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Chapter 3.1: Hemodynamic monitoring and support
for prevention and management of AKI
As discussed in Chapters 2.3 and Appendix D, patients with
AKI and at increased risk for AKI require careful attention to
be paid to their hemodynamic status. This is first because
hypotension results in decreased renal perfusion and, if severe
or sustained, may result in kidney injury. Second, the injured
kidney loses autoregulation of blood flow, a mechanism that
maintains relatively constant flow despite changes in pressure
above a certain point (roughly, a mean of 65mm Hg).
Management of blood pressure and cardiac output
require careful titration of fluids and vasoactive medication.
Vasopressors can further reduce blood flow to the tissues if
there is insufficient circulating blood volume. Conversely,
patients with AKI are also at increased risk for fluid overload
(see Chapter 3.2) and continued fluid resuscitation despite
increased intravascular volume can cause harm. Fluids and
vasoactive medications should be managed carefully and in
concert with hemodynamic monitoring. Hemodynamic
evaluation and monitoring are discussed in Appendix D.
In this chapter therapies aimed at correcting hemo-
dynamic instability will be discussed. Available therapies to
manage hypotension include fluids, vasopressors and proto-
cols which integrate these therapies with hemodynamic goals.
There is an extensive body of literature in this field and for a
broader as well as more in depth review the reader is directed
to the various reviews and textbooks devoted to critical care
and nephrology.70–81
FLUIDS
3.1.1: In the absence of hemorrhagic shock, we suggest
using isotonic crystalloids rather than colloids
(albumin or starches) as initial management for
expansion of intravascular volume in patients at
risk for AKI or with AKI. (2B)
RATIONALE
Despite the recognition of volume depletion as an important
risk factor for AKI, there are no randomized controlled trials
(RCTs) that have directly evaluated the role of fluids vs.
placebo in the prevention of AKI, except in the field of
contrast-induced acute kidney injury (CI-AKI) (see Chapter
4.4). It is accepted that optimization of the hemodynamic
status and correction of any volume deficit will have a
salutary effect on kidney function, will help minimize further
extension of the kidney injury, and will potentially facilitate
recovery from AKI with minimization of any residual func-
tional impairment. AKI is characterized by a continuum
of volume responsiveness through unresponsiveness
(Figure 8),78,82 and large multicenter studies have shown
that a positive fluid balance is an important factor associated
with increased 60-day mortality.78,83,84
The amount and selection of the type of fluid that should
be used in the resuscitation of critically ill patients is still
controversial. This guideline focuses on the selection of the
fluid (colloid vs. crystalloid fluid in the prevention and early
management of AKI). The three main end-points of the
studies explored were the effects on mortality, need for RRT,
and—if possible—the incidence of AKI. Although many
trials have been conducted to compare fluid types for
resuscitation, studies without AKI outcomes were not
systematically reviewed for this Guideline. Suppl Table 1
summarizes the RCTs examining the effect of starch for the
prevention of AKI.
Albumin vs. Saline
The role of albumin physiology in critically ill patients, and
the pros and cons for administering albumin to hypoalbu-
minemic patients, have recently been discussed.85 Results of
the Saline vs. Albumin Fluid Evaluation (SAFE) study, a RCT
comparing 4% human albumin in 0.9% saline with isotonic
saline in ICU patients, seem to indicate that albumin is safe,
albeit no more effective than isotonic saline (the standard of
care choice of isotonic sodium chloride in most centers) for
fluid resuscitation. SAFE demonstrated further no difference
in renal outcomes, at least based on the need for and
duration of RRT.86 The SAFE study was a double-blind study
and it was noted that patients in the albumin arm received
27% less study fluid compared to the saline arm (2247 vs.
3096ml) and were approximately 1 l less positive in overall
fluid balance.86 Furthermore, very few patients in the trial
received large volume fluid resuscitation (45 l) and thus the
results may not be applicable to all patients. The Work Group
noted that while isotonic crystalloids may be appropriate for
initial management of intravascular fluid deficits, colloids
may still have a role in patients requiring additional fluid.
http://www.kidney-international.org chapte r 3 .1
& 2012 KDIGO
Kidney International Supplements (2012) 2, 37–68 37
Hydroxyethylstarch vs. Saline
Hydroxyethylstarch (HES) is a widely used, relatively
inexpensive alternative to human albumin for correcting
hypovolemia. Different HES preparations are available that
vary with regard to concentration, mean molecular weight
(MW), molar substitution, and substitution of hydroxyethyl
for hydroxyl groups. The mean MW of the different HES
preparations ranges between 70 000 and 670 000 Da. The
colloid osmotic pressure effect is strongly dependent upon
the concentration of colloid in the solution; e.g., 6% HES is
iso-oncotic, whereas 10% HES is hyperoncotic. The number
of hydroxyethyl groups per glucose molecule is specified by
the molar substitution, ranging between 0.4 (tetrastarch)
and 0.7 (heptastarch). Accordingly, HES solutions with a
molar substitution of 0.5 or 0.6 are referred to as
‘‘pentastarch’’ or ‘‘hexastarch’’, respectively. More recently,
tetrastarches (HES 130/0.4 and HES 130/0.42) have also been
introduced.87 High molecular substitution starch may impair
coagulation by reducing the concentration of factor VIII:
VIIIc and von Willebrand factor. Platelet activity may also be
affected by blockade of the platelet fibrinogen receptor
glycoprotein IIb/IIIa. Smaller starch molecules and those
with less molecular substitution produce negligible coagula-
tion defects.88
Aside from these negative effects on coagulation, develop-
ment of renal dysfunction has been a concern associated with
the use of mainly hypertonic HES. Hypertonic HES may
induce a pathological entity known as ‘‘osmotic nephrosis’’
with potential impairment of renal function.89 It has even
been recommended that ‘‘HES should be avoided in ICUs
and during the perioperative period’’ (for a summary of this
controversy, see de Saint-Aurin et al.90 and Vincent91).
The first major randomized trial in patients with sepsis
compared HES 200/0.60 to 0.66 with gelatin and showed a
greater incidence of AKI in the HES group, but no effect on
survival.92 Criticisms of this study include a higher baseline
SCr level in the HES group, small sample size, and short
follow-up duration of 34 days. In the Efficacy of Volume
Substitution and Insulin Therapy in Severe Sepsis (VISEP)
study,93 patients with severe sepsis were randomly assigned to
receive a hypertonic (10%) solution of low MW HES (HES
200/0.5), or an isotonic modified Ringer’s lactate solution.
Patients in the HES group received a median cumulative dose
of 70.4ml per kilogram of body weight. The mortality was
not significantly different, although showing a trend toward
greater mortality at 90 days. However, the hypertonic HES
group had a significantly higher rate of AKI (34.9% vs.
22.8%) and more days on which RRT was required (Suppl
Table 1). Also, this study has been criticized for: i) using a
hyperoncotic colloid solution with potentially harmful renal
effects as shown in experimental research;94 ii) markedly
exceeding the pharmaceutically recommended daily dose
limit for 10% HES 200/0.5 by more than 10% in 438% of
patients; and iii) pre-existing renal dysfunction in 10% of
study patients, which represents a contra-indication for
infusion of 10% HES 200/0.5.95 Posthoc analyses of the
VISEP study showed the cumulative dose of HES to be a
significant independent predictor for both mortality and
RRT at 90 days. The median cumulative dose of HES in the
VISEP Study was 70ml/kg compared to 31ml/kg in the study
by Schortgen et al.92
A systematic review of RCTs on the use of HES for fluid
management in patients with sepsis totaling 1062 patients,
including 537 patients from the VISEP study, showed an
almost two-fold increased risk of AKI with HES compared to
crystalloids.96 Given these limitations, the results of these
studies should be interpreted with caution. Furthermore, a
large, prospective observational study found that HES
infusion of any type (median volume 555ml/d; intraquartile
range 500–1000) did not represent an independent risk factor
for renal impairment.97; however, recently in a large cohort of
critically ill patients (approximately 8000 subjects), infusion
of 10% HES 200/0.5 instead of HES 130/0.4 appeared to be
an independent risk factor for RRT.87 Finally, a recent
comprehensive Cochrane review98 concluded that there is no
evidence from RCTs that resuscitation with colloids, instead
of crystalloids, reduces the risk of death in patients with
trauma, burns, or following surgery.
The mechanisms of colloid-induced renal injury are
incompletely understood, but may involve both direct
molecular effects and effects of elevated oncotic pressure.99
These concerns have led to the widespread adoption of lower
MW starches as iso-oncotic solution, as resuscitation fluids.
Theoretically, such solutions may have lower nephrotoxicity;
however, as yet, no appropriately powered prospective
randomized studies have reported the clinical benefit and
Figure 8 |Conceptual model for development and clinical
course of AKI. The concept of AKI includes both volume-
responsive and volume-unresponsive conditions. These
conditions are not mutually exclusive, and a given patient may
progress from one to the other. Time runs along the x-axis, and
the figure depicts a closing ‘‘therapeutic window’’ as injury
evolves and kidney function worsens. Biomarkers of injury and
function will begin to manifest as the condition worsens, but
traditional markers of function (e.g., urea nitrogen and creatinine)
will lag behind hypothetical ‘‘sensitive’’ markers of kidney injury.
Mortality increases as kidney function declines. AKI, acute kidney
injury. Reproduced from Himmelfarb J, Joannidis M, Molitoris B,
et al. Evaluation and initial management of acute kidney injury.
Clin J Am Soc Nephrol 2008; 3: 962–967 with permission from
American Society of Nephrology82 conveyed through Copyright
Clearance Center, Inc; accessed http://cjasn.asnjournals.org/
content/3/4/962.long
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safety of such solutions in comparison with crystalloids. A
recent study by Magder et al. compared 10% 250/0.45 HES to
isotonic saline in 262 patients who underwent cardiac
surgery.100 These investigators tested whether fewer patients
required catecholamines the morning after cardiac surgery
(a chief determinant of ICU discharge) with HES compared
to saline, and found indeed this was the case (10.9% vs.
28.8%; P¼ 0.001). Importantly, the study found no evidence
of nephrotoxicity: no difference in the daily creatinine, deve-
lopment of AKI by RIFLE criteria during hospital stay (16%
in both groups), or need for RRT (1% in each group).
Importantly, patients in the saline group received nearly 60%
more volume for fluid resuscitation in the ICU compared to
HES (887 vs. 1397ml; Po0.0001). While overall volumes
were small, advocates for colloid resuscitation will note that
this is exactly the reason colloids are preferred for patients
requiring large-volume resuscitation.
The tonicity of colloid preparations may also vary by
agent. A recent meta-analysis101 described 11 randomized
trials with a total of 1220 patients: seven evaluating
hyperoncotic albumin and four evaluating hyperoncotic
starch. Hyperoncotic albumin decreased the odds of AKI by
76% while hyperoncotic starch increased those odds by 92%
(odds ratio [OR] 1.92; CI 1.31–2.81; P¼ 0.0008). Parallel
effects on mortality were observed. This meta-analysis con-
cluded that the renal effects of hyperoncotic colloid solutions
appear to be colloid-specific, with albumin displaying
renoprotection and hyperoncotic starch showing nephro-
toxicity. A 7000-patient study comparing 6% HES 130/0.4 in
saline with saline alone was scheduled to begin in Australia
and New Zealand in 2010. This study will provide further
high-quality data to help guide clinical practice.102
Thus, the use of isotonic saline as the standard of care for
intravascular volume expansion to prevent or treat AKI is
based upon the lack of clear evidence that colloids are
superior for this purpose, along with some evidence that
specific colloids may cause AKI, in addition to higher costs. It
is acknowledged that colloids may be chosen in some patients
to aid in reaching resuscitation goals, or to avoid excessive
fluid administration in patients requiring large volume
resuscitation, or in specific patient subsets (e.g., a cirrhotic
patient with spontaneous peritonitis, or in burns). Similarly,
although hypotonic or hypertonic crystalloids may be used in
specific clinical scenarios, the choice of crystalloid with
altered tonicity is generally dictated by goals other than
intravascular volume expansion (e.g., hypernatremia or
hyponatremia). One of the concerns with isotonic saline is
that this solution contains 154mmol/l chloride and that
administration in large volumes will result in relative or
absolute hyperchloremia (for a review, see Kaplan et al.103).
Although direct proof of harm arising from saline-induced
hyperchloremia is lacking, buffered salt solutions approxi-
mate physiological chloride concentrations and their admin-
istration is less likely to cause acid-base disturbances.
Whether use of buffered solutions results in better outcomes
is, however, uncertain.
VASOPRESSORS
3.1.2: We recommend the use of vasopressors in conjunc-
tion with fluids in patients with vasomotor shock
with, or at risk for, AKI. (1C)
RATIONALE
Sepsis and septic shock are major contributing factors to
AKI7 and vasopressor requirement appears to be highly
associated with AKI in this population. Despite the high
prevalence of AKI during critical illness in general, and severe
sepsis specifically, success has been limited in improving the
outcome of this complication.104 Septic shock is the proto-
type of a high output–low resistance condition, although
severe pancreatitis, anaphylaxis, burns, and liver failure
share similar physiologic alterations. Persistent hypotension,
despite ongoing aggressive fluid resuscitation or after
optimization of intravascular volume in patients with shock,
places patients at risk for development of AKI. In the setting
of vasomotor paralysis, preservation or improvement of
renal perfusion can only be achieved through use of
systemic vasopressors once intravascular volume has been
restored.105
It is not known which vasopressor agent is most effective
for prevention or treatment of patients with AKI and septic
shock. Most studies have focused on norepinephrine,
dopamine, or vasopressin. Small open-label studies have
shown improvement in creatinine clearance (CrCl) following
a 6- to 8-hour infusion of norepinephrine106 or terlipres-
sin,107 while vasopressin reduced the need for norepinephrine
and increased urine output and CrCl.108 A large RCT109
comparing dopamine to norepinephrine as initial vasopres-
sor in patients with shock showed no significant differences
between groups with regard to renal function or mortality.
However, there were more arrhythmic events among the
patients treated with dopamine than among those treated
with norepinephrine, and a subgroup analysis showed that
dopamine was associated with an increased rate of death at
28 days among the patients with cardiogenic shock, but not
among the patients with septic shock or those with hypo-
volemic shock. Thus, although there was no difference in
primary outcome with dopamine as the first-line vasopressor
agent and those who were treated with norepinephrine, the
use of dopamine was associated with a greater number of
adverse events.109
Vasopressin is gaining popularity in the treatment of
shock refractory to norepinephrine.110 Compared to nor-
epinephrine, it increases blood pressure and enhances
dieresis, but has not as yet been proven to enhance survival
nor to reduce the need for RRT.111 A recent posthoc analysis
of the above mentioned RCT used the RIFLE criteria for AKI
to compare the effects of vasopressin vs. norepinephrine.112
In patients in the RIFLE-R category, vasopressin as compared
to norepinephrine was associated with a trend to a lower rate
of progression to F or L categories respectively, and a lower
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rate of use of RRT. Mortality rates in the R category patients
treated with vasopressin compared to norepinephrine were
30.8 vs. 54.7%, P¼ 0.01, but this did not reach significance in
a multiple logistic regression analysis. This study suggests
thus that vasopressin may reduce progression to renal failure
and mortality in patients at risk of kidney injury who have
septic shock. The Work Group concluded that current
clinical data are insufficient to conclude that one vasoactive
agent is superior to another in preventing AKI, but
emphasized that vasoactive agents should not be withheld
from patients with vasomotor shock over concern for kidney
perfusion. Indeed, appropriate use of vasoactive agents can
improve kidney perfusion in volume-resuscitated patients
with vasomotor shock.
PROTOCOLIZED HEMODYNAMIC MANAGEMENT
3.1.3: We suggest using protocol-based management of
hemodynamic and oxygenation parameters to
prevent development or worsening of AKI in
high-risk patients in the perioperative setting (2C)
or in patients with septic shock (2C).
RATIONALE
A resuscitation strategy devised for patients with hypotension
from septic shock that is based upon achieving specific
physiologic end-points within 6 hours of hospital admis-
sion has been termed Early Goal-Directed Therapy (EGDT).
This approach has been endorsed by the ‘‘Surviving
Sepsis Campaign’’113 and has gained considerable acceptance
despite only one, single-center, RCT evaluating its effective-
ness. This protocolized strategy, consisting of fluids, vaso-
active medication, and blood transfusions targeting physio-
logical parameters, is recommended by many experts for the
prevention of organ injury in septic-shock patients.
Similarly, protocolized care strategies in surgical patients
at high risk for postoperative AKI have been extensively
studied in an effort to provide optimal oxygen delivery to
tissues in the perioperative period. In these patients, goal-
directed therapy is defined as hemodynamic monitoring with
defined target values and with a time limit to reach these
stated goals. Together these protocols with bundled, hemo-
dynamic, and tissue-support measures have the potential to
reduce the risk of AKI following major surgical procedures
in high-risk patients (e.g., age 460 years, emergent surgery,
elevated American Society of Anesthesiologists score,
preoperative comorbid illnesses).
Protocolized hemodynamic management strategies
in septic shock
Early fluid resuscitation in the management of hypotensive
patients with septic shock has been a standard treatment
paradigm for decades.93,113,114 What has not been clear,
however, is how much fluid to give, for how long, or what
type of fluid therapy is optimal in the physiologic support of
septic shock.93,113,114 In 2001, Rivers et al.115 published the
results of a small (n¼ 263), open-label, single-center study
that compared a treatment protocol that the authors referred
to as EGDT in the emergency management of septic shock.
EGDT is predicated upon the premise that an early,
protocolized resuscitation program with predefined physio-
logic end-points will prevent organ failure and improve the
outcome of patients presenting with septic shock.
Hypotensive patients with severe infection are rapidly
assessed for evidence of tissue hypoperfusion and micro-
circulatory dysfunction by mean arterial blood pressure
measurement and plasma lactate levels.115 Blood lactate levels
are neither sensitive nor specific but are readily available
measures of tissue hypoperfusion and do correlate with
adverse outcomes in sepsis.116,117 Early recognition of septic
shock then initiates a protocol of resuscitation with the goal
of reestablishing tissue perfusion in patients within 6 hours of
diagnosis. The physiologic goals are: i) return of mean
arterial blood pressure to X65mm Hg; ii) central venous
pressure between 8–12mm Hg; iii) improvement in blood
lactate levels; iv) central venous oxygen saturation (ScvO2)
470%; and v) a urine output of X0.5ml/kg/h.
In the study by Rivers et al. the protocol-driven process
resulted in more rapid use of fluids, more blood transfusions,
and in a small number of patients, earlier use of dobutamine
over the 6-hour time period than standard emergency care.
The in-hospital mortality rate in the control group was
46.5% vs. 30.5% in the EGDT group (Po0.01).115 Follow-up,
predominantly observational studies, have found less dra-
matic but generally similar effects,118–122 though not without
exception.123
The Rivers study did not specifically look at AKI out-
comes, but multiple-organ function-scoring systems (i.e.,
APACHE II and SAPS 2) both showed significant improve-
ments with EGDT. In a subsequent study, prevention of
AKI was significantly improved in patients randomized to a
modified EGDT strategy (without measurement of ScvO2)
compared to a standard-care group.119 Criticisms of the
Rivers study include: i) a complex, multistep protocol for
which individual interventions have not been validated; ii)
the use of a treatment team in the active-therapy arm, thus
risking a Hawthorn effect; iii) high mortality in the standard-
care arm; and iv) the study was a small single-center study.
Three large multicenter clinical trials in the USA, UK, and
Australia are currently underway to definitively evaluate this
promising therapy.
Goal-directed therapy for hemodynamic support during
the perioperative period in high-risk surgical patients
Efforts to improve tissue oxygen delivery by optimizing
hemodynamic support in high-risk surgical patients to
prevent AKI and other adverse patient outcomes have been
investigated for many years.124–126 A recent meta-analysis of
these studies by Brienza et al.127 concluded that protocolized
therapies (regardless of the protocol) with specific physio-
logical goals can significantly reduce postoperative AKI.
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A major problem in interpreting these studies is the lack of
standardized hemodynamic and tissue oxygenation targets
and management strategies used to verify the efficacy of these
measures over standard perioperative care. A heterogeneous
collection of study populations, types of surgical procedures,
monitoring methods, and treatment strategies comprise this
recent meta-analysis.127 The basic strategy of goal-directed
therapy to prevent AKI in the perioperative period is based
on protocols that avoid hypotension, optimize oxygen
delivery, and include careful fluid management, vasopressors
when indicated, and inotropic agents and blood products if
needed.127
The relative merits and risk:benefit ratio of each discrete
element of EGDT in the successful resuscitation of patients
with septic shock requires further study. Given the limita-
tions of the current studies and lack of comparative
effectiveness studies comparing individual protocols, we
can only conclude that protocols for resuscitation in the
setting of septic shock and high-risk surgery appear to be
superior to no protocol.
RESEARCH RECOMMENDATIONS
K Randomized trials of isotonic crystalloid vs. colloid
therapy for intravascular volume expansion to prevent
or treat AKI should be conducted in a variety of settings
(critical illness, high-risk surgery, sepsis), including
patient subsets. In particular, colloids may improve
efficiency of fluid resuscitation but some (starch) also
carry some concerns regarding effects on the kidneys. If
colloid results in less volume overload, it may lead to
improved outcomes.
K Comparisons of specific solutions, with specific electrolyte
composition or colloid type, for effectiveness in preventing
AKI should be conducted. Specifically, there is a need to
examine physiologic electrolyte solutions vs. saline.
K Studies are needed that compare different types of
vasopressors for prevention and treatment of AKI in
hemodynamically unstable patients. Some evidence
suggests that certain vasopressors may preserve renal
function better than others (e.g., vasopressin analogues
vs. catecholamines) and studies are needed to compare
them in this setting.
K The choice of a target mean arterial perfusion pressure
range of 65–90mm Hg as a component of resuscitation
(perhaps in the context of age, chronic blood pressure, or
other comorbidities) also needs further study.
K The specific components of goal-directed therapy that
accrue benefits for patients at risk for AKI need to be
determined. Is it the timing of protocolized hemodynamic
management that is beneficial: prophylactically in high-
risk surgical patients, or early in the course of severe sepsis?
In contrast to the benefits of prophylactic or EGDT,
protocolized use of inotropes to normalize mixed venous
oxygen saturation or supranormalize oxygen delivery in
‘‘late’’ critical illness did not result in decreased AKI128 or
improved outcomes.128,129 Alternatively, is it attention
to hemodynamic monitoring, the protocol itself that
standardizes supportive care to achieve the stated goals, or
a single or combination of the multiple possible interven-
tions that improves outcome? Thus, further research is
required to determine the specific components of goal-
directed therapy that accrue benefits for patients at risk for
AKI, if such benefits actually occur.
SUPPLEMENTARY MATERIAL
Supplementary Table 1: Summary table of RCTs examining the effect
of starch for the prevention of AKI.
Appendix D: Evaluation and General Management Guidelines for
Patients with AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
Kidney International Supplements (2012) 2, 37–68 41
chapte r 3 .1
Chapter 3.2: General supportive management of
patients with AKI, including management of
complications
Supportive management to prevent AKI was discussed in the
previous chapter and, for many patients, many of the supportive
therapies will continue even if AKI develops. Furthermore,
an important goal of early management of AKI is to prevent
further injury and to facilitate recovery of renal function. These
goals can often best be achieved by strict attention to supportive
therapy. However, as renal function deteriorates, complications
arise that require different management. Some of these issues
have been discussed in Chapter 2.3 and several books have
been devoted, in large part, to management of the many
complications that arise from AKI130–133; the reader is referred
to these sources. Particular attention should be given to the
assessment of the circulating volume and fluid administration,
the prevention and/or treatment of hyperkalemia and metabolic
acidosis, the knowledge of the changes in pharmacokinetics of
many drugs with discontinuation of all potentially nephrotoxic
drugs, and dose adaptation of drugs excreted by the kidneys to
the patient’s renal function. Finally, many of the other chapters
in this section of the guideline deal with supportive measures
(e.g., diuretics for fluid management).
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Chapter 3.3: Glycemic control and nutritional support
GLYCEMIC CONTROL IN CRITICAL ILLNESS: RENAL EFFECTS
AND OUTCOMES
3.3.1: In critically ill patients, we suggest insulin
therapy targeting plasma glucose 110–149mg/dl
(6.1–8.3mmol/l). (2C)
RATIONALE
As outlined in a recent review,134 stress hyperglycemia is a
distinctive clinical feature of critical illness. Stress mediators,
and central and peripheral insulin resistance appears pivotal
to the occurrence of stress hyperglycemia. Inflammatory
mediators and counter-regulatory hormones have been
shown to impede crucial elements of the insulin-signaling
pathway. Still, exogenous insulin administration normalizes
blood glucose levels in this setting. Insulin treatment may
counteract hepatic insulin resistance during acute critical
illness. Extensive observational data have shown a consistent,
almost linear, relationship between blood glucose levels in
patients hospitalized with MI and adverse clinical outcomes,
even in patients without established diabetes.135,136
It has never been entirely clear, however, whether glycemia
serves as a mediator of these outcomes or merely as a marker
of the sickest patients, who present with the well-known
counter-regulatory stress response to illness.137 Interestingly,
Kosiborod et al.135 recently showed, in a population with MI,
that while hypoglycemia was associated with increased
mortality, this risk was confined to patients who developed
spontaneous hypoglycemia. In contrast, iatrogenic hypo-
glycemia after insulin therapy was not associated with higher
mortality risk.
Tight glycemic control is frequently used in patients at risk
of AKI, and in the management of those who develop AKI. It
has been proposed that tight glycemic control can reduce the
incidence and severity of AKI. Since the landmark trial of Van
den Berghe et al.,138 additional studies provided initial
confirmation of the benefits (reduced morbidity and
mortality), and some additional mechanistic insights of tight
glycemic control in critically ill patients.139 Further secondary
analysis of the original trial, which was conducted in 1548
mechanically ventilated surgical ICU patients, found that
intensive insulin therapy (IIT) target plasma glucose
80–110mg/dl (4.44–6.11mmol/l) was associated with sub-
stantial cost savings compared to conventional insulin
therapy (CIT) target plasma glucose 180–200mg/dl (9.99–
11.1mmol/l).140 However, when Van den Berghe et al.
repeated their original study in a different population of
critically ill patients (medical rather than surgical ICU
patients), the primary end-point of in-hospital mortality
did not differ between groups (40% CIT group vs. 37.3% IIT
group; P¼ 0.33).141 As in the original surgical ICU study, a
variety of secondary end-points were improved in this study,
including a lower incidence of AKI and need for RRT. In the
original surgical ICU study, severe AKI (peak SCr42.5mg/dl
[4221 mmol/l]) developed in 7.2% of the IIT group,
compared to 11.2% of the CIT group (P¼ 0.04); the
incidence of RRT was also lower in the IIT group than the
CIT group (4.8% vs. 8.2%, respectively; P¼ 0.007).138 In the
medical ICU study, the IIT group similarly had a significantly
lower rate of AKI (doubling of SCr, 5.4%) than the CIT
group (8.9%, P¼ 0.04), although RRT incidence was not
decreased.141 In a recent analysis, Schetz et al.142 combined
the renal end-points of both of these trials and used a modi-
fied version of the RIFLE classification of AKI to demonstrate
that tight glycemic control reduced the incidence of severe
AKI (peak SCr increments two- or three-fold increased from
baseline) from 7.6% to 4.5% (P¼ 0.0006) in a combined
patient population of 2707. The need for RRT was not
decreased in the overall population or the medical ICU
population, but was significantly lower in the surgical ICU
patients managed with IIT (4% vs. 7.4%, P¼ 0.008).
Several newer studies have provided additional insight
concerning the efficacy and safety of tight glycemic control in
critically ill patients.93,95,143–146 Thomas et al.145 conducted a
systematic review of randomized trials of tight glycemic
control in 2864 critically ill patients, and found a 38% risk
reduction of AKI with IIT, and a nonsignificant trend towards
less acute dialysis requirement. However, IIT was also
associated with a greater than four-fold increase in the risk
of hypoglycemia. A body of literature demonstrating that
uncontrolled hyperglycemia was associated with increased
AKI following cardiac surgery led to the conduct of a 400-
patient, single-center RCT of tight vs. conventional intra-
operative glucose control.143,144 The investigators found that
this approach did not decrease perioperative morbidity or
mortality (included in a composite end-point that included
AKI within 30 days of surgery): the composite end-point
occurred in 44% of the IIT group vs. 46% of the CIT group.
Although the incidence of hypoglycemia was similar in the
groups, there was a significantly higher incidence of stroke in
the IIT group (4.3%) compared to the CIT group (0.54%), as
well as trends towards higher mortality and more post-
operative heart block in the IIT group, raising concerns about
the safety of this approach.
Further prospective comparison of IIT vs. CIT in critically
ill septic patients was provided in the VISEP trial, which
also incorporated a comparison on crystalloid vs. colloid
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infusions in a 2 2 factorial design.93 Patients with severe
sepsis or septic shock in 18 ICUs were randomized to IIT
(target glycemia 80–110mg/dl [4.44–6.11mmol/l]; n¼ 247)
or CIT (target glycemia 180–200mg/dl [9.99–11.1mmol/l];
n¼ 290) (Suppl Tables 2 and 3). There were no significant
differences in 28-day or 90-day mortality, Sequential Organ
Failure Assessment scores, or AKI rates between the groups.
However, hypoglycemia (blood glucose level o40mg/dl
[o2.22mmol/l]) was more frequent in the IIT group (12%
vs. 2%; Po0.001) and led to early termination of the IIT
study arm. Following publication of this study, Thomas et al.,
updated the meta-analysis (discussed above) to include these
data, and reported that, with the addition of the VISEP data,
the analysis of a 3397-patient group found a 36% risk
reduction of AKI with IIT, but this pooled estimate was no
longer statistically significant (relative risk [RR] 0.74; 95% CI
0.47–1.17).95 In a detailed review of the VISEP trial, Thomas
et al., also noted that another multicenter mixed ICU trial of
intensive insulin therapy (the GLUCOCONTROL Study:
Comparing the effects of two glucose control regimens by
insulin in intensive care unit patients; available at: http://
www.clinicaltrials.gov/ct/show/NCT00107601) was stopped
after 1101 patients were enrolled because of greater rates of
hypoglycemia with IIT.95 Such data have raised significant
concerns regarding the effectiveness and safety of using IIT
with tight glycemic control to prevent or ameliorate
morbidity and mortality in patients at high risk of AKI and
other forms of organ injury.
The recent meta-analysis of IIT vs. CIT by Wiener et al.146
continued to find a greater incidence of hypoglycemia with
IIT, but the balance of evidence now suggests no improve-
ment in survival with this approach. Twenty-nine RCTs
totaling 8432 patients contributed data for this meta-analysis.
Twenty-seven studies reported no difference in hospital
mortality (21.6% in IIT vs 23.3% in CIT) with a pooled RR
of 0.93 (95% CI 0.85–1.03; P¼NS). Nine studies reported no
difference in incidence of new RRT. There was a significant
benefit of tight glycemic control in reducing the incidence of
septicemia but this was associated with a significantly
increased risk of hypoglycemia (blood glucose o40mg/dl
[o2.22mmol/l]) in patients randomized to IITwith a pooled
RR of 5.13 (95% CI 4.09–6.43; Po0.05).
In summary, pooled analysis of early multicenter studies
has failed to confirm the early observations of beneficial
effects of IIT on renal function; the risk of hypoglycemia with
this approach is significant, and even the survival benefits of
IIT are in doubt. More recently, the international Normogly-
cemia in Intensive Care Evaluation and Survival Using
Glucose Algorithm Regulation (NICE-SUGAR) study, with a
targeted enrolment of 6100 patients, set out to definitively
determine the risk-benefit comparison of tight glycemic
control in critically ill patients (Suppl Table 3).147,148 In this
trial, adult patients were randomized within 24 hours after
admission to an ICU to receive either intensive glucose
control (target blood glucose range of 81–108mg/dl [4.50–
5.99mmol/l]), or conventional glucose control (target of
p180mg/dl [p9.99mmol/l]).148 The primary outcome was
mortality from any cause within 90 days after randomization.
The two groups had similar characteristics at baseline. A total
of 829 patients (27.5%) in the intensive-control group and
751 (24.9%) in the conventional-control group died (OR
for intensive control, 1.14; 95% CI 1.02–1.28; P¼ 0.02). The
treatment effect did not differ significantly between surgical
patients and medical patients. There was no significant
difference between the two treatment groups in incidence of
new RRT (15.4% vs. 14.5%), respectively. Severe hypo-
glycemia (blood glucose level p40mg/dl [p2.22mmol/l])
was reported in 6.8% in the intensive-control group and in
0.5% in the conventional-control group (Po0.001). In
summary, the largest randomized trial of intensive vs.
conventional insulin therapy found that intensive glucose
control actually increased mortality among adults in the ICU:
a blood glucose target of p180mg/dl (p9.99mmol/l)
resulted in lower mortality than did a target of 81–108mg/
dl (4.50–5.99mmol/l). Furthermore, this trial confirmed the
consistent finding of an increased incidence of hypoglycemia
associated with IIT, without any proven benefit in reducing
mortality, organ dysfunction, or bacteremia.
There were some methodological differences between the
Leuven and NICE-SUGAR studies, possibly explaining the
different outcomes.149 These comprised different target
ranges for blood glucose in control and intervention groups,
different routes for insulin administration and types of infu-
sion pumps, different sampling sites, and different accuracies
of glucometers, as well as different nutritional strategies and
varying levels of expertise. Finally, Griesdale et al.150 per-
formed a meta-analysis of trials of intensive vs. conventional
glycemic control that included most of the studies in the
Wiener meta-analysis, in addition to some newer studies,
including data supplied by the NICE-SUGAR investigators.
All 26 trials that reported mortality found a pooled RR of
death with IIT compared to CIT of 0.93 (95% CI 0.83–1.04).
Among the 14 trials reporting hypoglycemia, the pooled RR
with IIT was 6.0 (95% CI 4.5–8.0). However, in subset
analysis, patients in surgical ICUs appeared to benefit from
IIT while patients in the other ICU settings (medical or
mixed) did not. Although results from the early trials were
better in studies that included surgical138 rather than purely
medical ICU patients141, and this latest meta-analysis appears
to confirm that trend, it should be noted that no such
phenomenon was noted in the NICE-SUGAR trial. Overall,
the data do not support the use of IIT aiming to control
plasma glucose below 110mg/dl (6.11mmol/l) in critically ill
patients, although subset analyses suggest that further trials
may disclose benefits in perioperative patients, and perhaps
through the use of less-intensive glucose control targets.
Considering the balance between potential benefits and
harm (see Suppl Table 2), the Work Group suggests using
insulin for preventing severe hyperglycemia in critically ill
patients, but in view of the danger of potentially serious
hypoglycemia, we recommend that the average blood glucose
should not exceed 150mg/dl (8.33mmol/l), but that insulin
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therapy should not be used to lower blood glucose to less
than 110mg/dl (6.11mmol/l). The Work Group recognizes
that these proposed thresholds have never directly been
examined in RCTs but are interpolated from the comparisons
tested in the trials so far.
NUTRITIONAL ASPECTS IN THE PREVENTION AND
TREATMENT OF CRITICALLY ILL PATIENTS WITH AKI
Protein-calorie malnutrition is an important independent
predictor of in-hospital mortality in patients with AKI. In a
prospective study of 300 AKI patients, 42% presented with
signs of severe malnutrition on admission.151
The nutritional management of AKI patients must
consider the metabolic derangements and proinflammatory
state associated with renal failure, the underlying disease
process and comorbidities, as well as the derangements in
nutrient balance caused by RRT. Very few systematic studies
have assessed the impact of nutrition on clinical end-points
used in these guidelines (i.e., mortality, need for RRT,
and incidence of AKI). Recommendations are therefore
largely based on expert opinion. Several expert panels have
developed clinical practice guidelines for the nutritional
management of patients with AKI, whether treated with or
without RRT.152–156 A recent narrative review has also
provided updated information on this topic.157
3.3.2: We suggest achieving a total energy intake of
20–30 kcal/kg/d in patients with any stage of AKI. (2C)
RATIONALE
Carbohydrate metabolism in AKI is characterized by
hyperglycemia due to peripheral insulin resistance158,159
and accelerated hepatic gluconeogenesis, mainly from con-
version of amino acids released during protein catabolism
that cannot be suppressed by exogenous glucose infusions.160
In addition, hypertriglyceridemia commonly occurs due
to inhibition of lipolysis. The clearance of exogenously
administered lipids can be reduced.161 The modifications of
energy metabolism are usually not caused by AKI per se but
related to acute comorbidities and complications.162 Energy
consumption is not increased by AKI. Even in multiple-organ
failure, the energy expenditure of critically ill patients
amounts to not more than 130% of resting energy
expenditure. The optimal energy-to-nitrogen ratio during
AKI has not been clearly determined. In a retrospective study
of AKI patients undergoing continuous venovenous hemofil-
tration (CVVH), less negative or weakly positive nitrogen
balance was associated with an energy intake of approxi-
mately 25 kcal/kg/d.163 In a randomized trial in AKI patients
comparing 30 and 40 kcal/kg/d energy provision, the higher
energy prescription did not induce a more positive nitrogen
balance but was associated with a higher incidence of
hyperglycemia and hypertriglyceridemia and a more positive
fluid balance.164 These observations provide a rationale to
maintain a total energy intake of at least 20, but not more
than 25–30 kcal/kg/d, equivalent to 100–130% of resting
energy expenditure. Energy provision should be composed of
3–5 (maximum 7) g per kilogram body weight carbohydrates
and 0.8–1.0 g per kilogram body weight fat.
3.3.3: We suggest to avoid restriction of protein intake
with the aim of preventing or delaying initiation of
RRT. (2D)
3.3.4: We suggest administering 0.8–1.0 g/kg/d of protein
in noncatabolic AKI patients without need for
dialysis (2D), 1.0–1.5 g/kg/d in patients with AKI on
RRT (2D), and up to a maximum of 1.7 g/kg/d in
patients on continuous renal replacement therapy
(CRRT) and in hypercatabolic patients. (2D)
RATIONALE
Protein hypercatabolism driven by inflammation, stress,
and acidosis is a common finding in critically ill
patients.157,165,166 The optimal amount of protein supple-
mentation in AKI patients is unknown. Patients with AKI are
at high risk of malnutrition. Since malnutrition is associated
with increased mortality in critically ill patients, nutritional
management should aim at supplying sufficient protein to
maintain metabolic balance. Hence, nutritional protein
administration should not be restricted as a means to
attenuate the rise in BUN associated with declining GFR. On
the other hand, there is little evidence that hypercatabolism
can be overcome simply by increasing protein intake to
supraphysiologic levels. While, in a crossover study of AKI
patients, nitrogen balance was related to protein intake
and was more likely to be positive with intakes larger than
2 g/kg/d,167 only 35% of patients achieved a positive nitrogen
balance in a study applying a nutrient intake as high as
2.5 g/kg/d protein.168 No outcome data are currently
available concerning the clinical efficacy and the safety of
such high protein intakes, which may contribute to acidosis
and azotemia, and increase dialysis dose requirements.
Due to their continuous nature and the high filtration
rates, CRRT techniques can better control azotemia and fluid
overload associated with nutritional support but may also
result in additional losses of water-soluble, low-molecular-
weight substances, including nutrients.169 Normalized pro-
tein catabolic rates of 1.4 to 1.8 g/kg/d have been reported
in patients with AKI receiving CRRT.170–172 In a recent study
in critically ill cancer patients with AKI and treated with
sustained low-efficiency dialysis (SLED), those with higher
BUN and serum albumin levels, which were associated with
infusion of higher amount of total parenteral nutrition, had a
lower mortality risk.173
In CRRT, about 0.2 g amino acids are lost per liter of
filtrate, amounting to a total daily loss of 10–15 g amino
acids. In addition, 5–10 g of protein are lost per day,
depending on the type of therapy and dialyzer membrane.
Similar amounts of protein and amino acids are typically lost
by peritoneal dialysis (PD). Nutritional support should
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account for the losses related to CRRT, including PD, by
providing a maximum of 1.7 g amino acids/kg/d.
3.3.5: We suggest providing nutrition preferentially via
the enteral route in patients with AKI. (2C)
RATIONALE
Enteral feeding may be more difficult in patients with AKI
because of impaired gastrointestinal motility and decreased
absorption of nutrients secondary to bowel edema.174
Moreover, multiple factors negatively affect gastrointestinal
function in critically ill patients, e.g., medications (sedatives,
opiates, catecholamines, etc.), glucose and electrolyte dis-
orders, diabetes, or mechanical ventilation. However, the
provision of nutrients via the gut lumen helps maintain gut
integrity, decreases gut atrophy, and decreases bacterial and
endotoxin translocation. Furthermore, AKI is a major risk
factor for gastrointestinal hemorrhage.175 Enteral nutrition
should exert protective effects on the risk of stress ulcers or
bleeding. Clinical studies have suggested that enteral feeding
is associated with improved outcome/survival in ICU
patients.176,177 Hence, enteral nutrition is the recommended
form of nutritional support for patients with AKI. If oral
feeding is not possible, then enteral feeding (tube feeding)
should be initiated within 24 hours, and has been shown to
be safe and effective.178
Pediatric considerations
In children with AKI, physiological macronutrient require-
ments are age-dependent, reflecting the developmental
dynamics of growth and metabolism. Research exploring
nutritional requirements in children with critical illness and
AKI is limited to observational studies. With respect to calorie
provision, it is generally agreed that critically ill children,
like adults, should receive 100–130% of the basal energy
expenditure, which can be estimated with acceptable precision
and accuracy by the Caldwell-Kennedy equation179: (resting
energy expenditure [kcal/kg/d]¼ 22þ 31.05weight [kg]þ
1.16 age [years]).
In a recent survey of the nutritional management of 195
children with AKI on CRRT, the maximal calorie prescription
in the course of treatment averaged 53, 31, and 21 kcal/kg/d,
and that for protein intake 2.4, 1.9, and 1.3 g/kg/d in children
agedo1, 1–13, and413 years, respectively.180 Although not
validated by outcome studies, these figures provide an
orientation for the macronutrient supply typically achieved
in and tolerated by children with AKI receiving CRRT.
RESEARCH RECOMMENDATIONS
K The risk-benefit ratio of diets with low, medium, and
high protein contents in different stages of AKI should be
addressed in RCTs.
K Given gastrointestinal tract dysfunction in AKI, the
possible benefit of enteral vs. parenteral feeding in AKI
patients should be further evaluated in prospective RCTs.
SUPPLEMENTARY MATERIAL
Supplementary Table 2: Evidence profile of RCTs examining insulin vs.
conventional glucose therapy for the prevention of AKI.
Supplementary Table 3: Summary table of RCTs examining the effect
of insulin for the prevention of AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
46 Kidney International Supplements (2012) 2, 37–68
chapte r 3 .3
Chapter 3.4: The use of diuretics in AKI
Diuretics are frequently used in patients at risk of AKI, and in
the management of those who develop AKI. Since fluid
overload is one of the major symptoms of AKI, diuretics are
often used for patients with AKI to facilitate fluid manage-
ment. Recent observational studies showed that 59–70% of
patients with AKI were given diuretics at the time of
nephrology consultation or before the start of RRT.181,182
In addition, oliguric AKI has a worse prognosis than
nonoliguric AKI and physicians often prescribe diuretics to
convert oliguric to nonoliguric AKI.183 Diuretics are also
used to control fluid balance and permit administration of
nutrition and medications. Furthermore, several diuretics
have potentially renoprotective effects that might prevent
development of AKI and hasten its recovery. However,
diuretics can also be harmful, by reducing the circulating
volume excessively and adding a prerenal insult, worsening
established AKI. Therefore, it is essential to evaluate
usefulness of diuretics to improve outcome of patients with
AKI, not just for fluid management.
3.4.1: We recommend not using diuretics to prevent
AKI. (1B)
3.4.2: We suggest not using diuretics to treat AKI, except
in the management of volume overload. (2C)
RATIONALE
Loop diuretics have several effects that may protect against
AKI. They may decrease oxygen consumption in the loop of
Henle by inhibiting sodium transport, thus potentially
lessening ischemic injury. Loop diuretics act at the luminal
surface of the thick ascending limb of the loop of Henle and
inhibit the Na-K-2Cl cotransporter,184,185 resulting in a loss
of the high medullary osmolality and decreased ability to
reabsorb water. Inhibition of active sodium transport also
reduces renal tubular oxygen consumption, potentially
decreasing ischemic damage of the most vulnerable outer
medullary tubular segments;183 therefore, furosemide might
protect kidneys against ischemic injury.186 Furosemide also
might hasten recovery of AKI by washing out necrotic debris
blocking tubules, and by inhibiting prostaglandin dehydro-
genase, which reduces renovascular resistance and increases
renal blood flow.186,187 Based on these properties, loop
diuretics might be expected to prevent or ameliorate AKI.
However, there are only minimal data to support this theory,
and there is some evidence of harm associated with loop
diuretic use to prevent or treat AKI.188–191 Furosemide is the
most commonly prescribed diuretic in the acute-care
setting,183–185 and a number of RCTs have tested whether
furosemide is beneficial for prevention or treatment of AKI.
Specifically, prophylactic furosemide was found to be
ineffective or harmful when used to prevent AKI after cardiac
surgery,189,190 and to increase the risk of AKI when given to
prevent CI-AKI.191 Epidemiologic data have suggested that
the use of loop diuretics may increase mortality in patients
with critical illness and AKI,181 along with conflicting data
that suggest no harm in AKI.182 Finally, furosemide therapy
was also ineffective and possibly harmful when used to treat
AKI.188,192
There is no evidence that the use of diuretics reduces the
incidence or severity of AKI. Ho et al.192,193 conducted two
comprehensive systematic reviews on the use of the loop
diuretic frusemide (furosemide) to prevent or treat AKI.
Furosemide had no significant effect on in-hospital mortality,
risk for requiring RRT, number of dialysis sessions, or even
the proportion of patients with persistent oliguria. Results
from the most recent review193 are shown in Figure 9 and
Figure 10. The primary prevention studies included patients
who underwent cardiac surgery,189 coronary angiography,191
and major general or vascular surgery.194 In two of these
studies, all participants had mild pre-existing renal impair-
ment. Two of the three studies reported mortality in patients
randomized to furosemide (n¼ 103) vs. placebo (n¼ 99),
with a pooled RR of 2.67 (95% CI 0.75–7.25; P¼ 0.15). All
three studies reported RRT incidence in patients randomized
to furosemide (n¼ 128) vs. placebo (n¼ 127), with a pooled
RR of 4.08 (95% CI 0.46–35.96; P¼ 0.21). Thus, subanalysis
to separate primary and secondary prevention trials did not
alter the conclusion that, within the sample size limitations
of this study, furosemide is not effective for the prevention
of AKI.
The systematic review and meta-analysis by Ho and
Power193 also included six studies that used furosemide to
treat AKI, with doses ranging from 600 to 3400mg/d
(Figure 9 and Figure 10).192 No significant reduction was
found for in-hospital mortality or for RRT requirement. The
largest single study of furosemide for treating AKI was
conducted by Cantarovich et al.,188 which included 338
patients with AKI requiring dialysis. Patients were randomly
assigned to the administration of either furosemide (25mg/
kg/d i.v. or 35mg/kg/d orally) or placebo. Although time to
reach 2 l/d of diuresis was shorter with furosemide (5.7 days)
than placebo (7.8 days, P¼ 0.004), there was no difference in
survival and number of dialysis sessions. At present, the
current evidence does not suggest that furosemide can reduce
mortality in patients with AKI.
Furosemide may, however, be useful in achieving fluid
balance to facilitate mechanical ventilation according to the
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lung-protective ventilation strategy in hemodynamically
stable patients with acute lung injury. On the other hand,
the literature also suggests that high-dose furosemide
(41 g/d) may cause ototoxicity. In the first meta-analysis
by Ho and Sheridan,192 high doses of furosemide (range
1–3.4 g/d) caused deafness or tinnitus more frequently than
the control (RR 3.97; 95% CI 1.00–15.78; P¼ 0.05). When
administered as continuous infusion a dose of 0.5mg/kg/
hour was not associated with ototoxicity.195 Taken together
with several small studies showing that the prophylactic use
of diuretics to prevent AKI actually increased AKI incidence,
these data raise significant concerns regarding use of loop
diuretics to prevent or treat AKI in any setting. We similarly
conclude that there is no evidence that the use of loop
diuretics reduces the severity of AKI, or improves outcomes
in this syndrome. Although the use of loop diuretics in early
or established AKI facilitates management of fluid balance,
hyperkalemia, and hypercalcemia, and is indicated for these
clinical purposes, any putative role in the prevention or
amelioration of AKI course is unproven.
Two recent studies have investigated whether the admin-
istration of furosemide to patients treated with CVVH could
be associated with a more rapid discontinuation of the
dialysis therapy. van der Voort et al., observed, as expected,
an increased urinary volume and sodium excretion, but this
intervention did not lead to a shorter duration of renal failure
Figure 9 | Effect of furosemide vs. control on all-cause mortality. Reprinted from Ho KM, Power BM. Benefits and risks of furosemide in
acute kidney injury. Anaesthesia 2010; 65: 283–293 with permission from John Wiley and Sons193; accessed http://onlinelibrary.wiley.com/
doi/10.1111/j.1365-2044.2009.06228.x/full
Figure 10 | Effect of furosemide vs. control on need for RRT. Reprinted from Ho KM, Power BM. Benefits and risks of furosemide in acute
kidney injury. Anaesthesia 2010; 65: 283–293 with permission from John Wiley and Sons193; accessed http://onlinelibrary.wiley.com/doi/
10.1111/j.1365-2044.2009.06228.x/full
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or more frequent renal recovery.195 The second study by
Uchino et al.,196 analyzed data from the B.E.S.T. kidney and
found that, from a total of 529 critically ill patients who
survived during CRRT, 313 patients were removed success-
fully from CRRT while 216 patients needed ‘‘repeat RRT’’
after temporary discontinuation. Urine output (during the 24
hours before stopping CRRT) was identified as a significant
predictor of successful cessation, but the predictive ability of
urine output was negatively affected by the use of diuretics.
Thus, a beneficial role for loop diuretics in facilitating
discontinuation of RRT in AKI is not evident.
Mannitol
Mannitol has been frequently used in the past for prevention
of AKI; however, most of the studies are retrospective,
underpowered, and, overall, the studies did not meet the
criteria of the Work Group to be included in formulation of
recommendations. Prophylactic mannitol has been promoted
in patients undergoing surgery. While in most of these
instances mannitol increases urine flow, it is highly probable
that mannitol does not convey additional beneficial effects
beyond adequate hydration on the incidence of AKI.
In radiocontrast-induced nephropathy, loop diuretics
and mannitol in one study have been shown to exacerbate
ARF.191 Weisberg et al.,197 randomized patients under-
going contrast-medium investigations to receive saline or
one of three renal vasodilator/diuretic drugs (dopamine
[2mg/kg/min], mannitol [15 g/dl in a one-half isotonic saline
solution given at 100ml/h] or atrial natriuretic peptide).
Dopamine, mannitol, and atrial natriuretic peptide were
associated with a much higher incidence of renal dysfunction
in diabetic subjects compared to patients receiving saline alone.
Mannitol is often added to the priming fluid of the
cardiopulmonary bypass system to reduce the incidence of
renal dysfunction, but the results of these studies are not very
convincing.198 Two small randomized trials—one in patients
with pre-existing normal renal function,199 the second in
patients with established renal dysfunction200—did not find
differences for any measured variable of renal function.
More convincing are the results obtained with the preventive
administration of mannitol, just before clamp release, during
renal transplantation.201,202 The sparse controlled data
available have shown that 250ml of mannitol 20% given
immediately before vessel clamp removal reduces the inci-
dence of post-transplant AKI, as indicated by a lower require-
ment of post-transplant dialysis. However, 3 months after
transplantation, no difference is found in kidney function
compared to patients who did not receive mannitol.203
It has also been suggested that mannitol is beneficial in
rhabdomyolysis by stimulating osmotic diuresis and by
lowering the intracompartmental pressure in the affected
crushed limbs204–206; again, these studies were either not
randomized or underpowered. A separate guideline on crush
injury associated with disasters, mainly earthquake victims, is
under preparation by the ISN Renal Disaster Relief Task
Force.
In summary, despite experimental animal data and the
anecdotal human evidence for the beneficial effects of
mannitol, there are no adequately powered prospective RCTs
comparing mannitol vs. other strategies. Based on these
considerations, the Work Group concludes that mannitol is
not scientifically justified in the prevention of AKI.
RESEARCH RECOMMENDATION
K Given the potential to mitigate fluid overload but also to
worsen renal function and possibly cause kidney injury,
further study is required to clarify the safety of loop
diuretics in the management of patients with AKI.
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Chapter 3.5: Vasodilator therapy: dopamine,
fenoldopam, and natriuretic peptides
DOPAMINE FOR THE PREVENTION OR TREATMENT OF AKI
Dopamine was once commonly used for renal protection in
the critically ill. However, with multiple negative studies,
including a randomized, double-blind, placebo-controlled
trial of adequate size and power,207 its use has been
abandoned by most. Low-dose dopamine administration
(1–3 mg/kg/min) to healthy individuals causes renal vasodila-
tion, natriuresis, and increased GFR; because of these effects,
it has been given as prophylaxis for AKI associated with
radiocontrast administration, repair of aortic aneurysms,
orthotopic liver transplantation, unilateral nephrectomy,
renal transplantation, and chemotherapy with interferon.208
The majority of prevention trials with low-dose dopamine
have been small, inadequately randomized, of limited
statistical power, and with end-points of questionable clinical
significance. Furthermore, recent data suggest that the renal
vasodilatory effect of dopamine found in healthy populations
is not preserved in patients with AKI. Using Doppler
ultrasound, Lauschke et al.209 found that dopamine signi-
ficantly increased renal vascular resistance in AKI patients.
Kellum and Decker210 found no benefit of dopamine for
prevention or therapy of AKI in an adequately-powered
meta-analysis, and Marik211 found no benefit in a systematic
review.
There is also limited evidence that the use of dopamine to
prevent or treat AKI causes harm. Although the meta-analysis
by Friedrich et al.,212 found no significant increase in adverse
events or evidence of harm from low-dose dopamine, there is
significant literature demonstrating adverse effects of dopa-
mine, even at low doses. It can trigger tachyarrhythmias
and myocardial ischemia, decrease intestinal blood flow,
cause hypopituitarism, and suppress T-cell function.208 Taken
together with the lack of positive trials to support the use of
dopamine for AKI prevention or therapy, the aforementioned
potential deleterious effects of this drug provide additional
arguments for abandoning its use entirely for the prevention
and therapy of AKI.
3.5.1: We recommend not using low-dose dopamine to
prevent or treat AKI. (1A)
RATIONALE
In their meta-analysis, Friedrich et al.,212 did not specifically
separate prophylactic trials from trials where dopamine was
used therapeutically in patients with established AKI, because
many of the original trials failed to do so.210 The authors
analyzed 61 randomized or quasi-randomized controlled
trials of low-dose dopamine, and found no improvement of
survival (Figure 11), no decrease in dialysis requirement
(Figure 12), no improvement in renal function, and
improved urine output only on the first day of dopamine
therapy.212 Similarly, although there were trends towards
transiently greater urine output, lower SCr, and higher GFR
in dopamine-treated patients on day 1 of therapy (but not
days 2 and 3), there was no evidence of a sustained beneficial
effect on renal function. In an earlier systematic review,
Kellum et al.,210 performed an analysis of studies that
reported incidence of AKI as an outcome, which developed in
15.3% in the dopamine arms and 19.5% in the control arms
(RR 0.79 [0.54–1.13]). Similar to the earlier analysis by
Kellum et al., restriction of the Work Group’s analysis to
prevention trials did not disclose any benefit of dopamine vs.
placebo therapy. Similarly, analysis of adequate trials
restricted to patients treated for AKI does not suggest a
benefit of dopamine therapy. Specifically, a relatively large
randomized, placebo-controlled trial in 328 critically ill
patients with early AKI sufficiently powered to detect a small
benefit was reported.207 There was no effect of low-dose
dopamine on renal function, need for dialysis, ICU or
hospital length of stay (LOS), or mortality (Suppl Table 4).
Taken together, these analyses found no evidence that
dopamine therapy is effective in the prevention or treatment
of AKI.
FENOLDOPAM FOR THE PREVENTION OR TREATMENT OF AKI
Fenoldopam mesylate is a pure dopamine type-1 receptor
agonist that has similar hemodynamic renal effects as
low-dose dopamine, without systemic a- or b-adrenergic
stimulation.213
3.5.2: We suggest not using fenoldopam to prevent or
treat AKI. (2C)
RATIONALE
The results of animal experiments and small human studies
measuring perioperative GFR in patients undergoing coro-
nary artery bypass graft and aortic cross-clamp surgery
suggested that fenoldopam might prevent or ameliorate the
course of AKI.139 Cogliati et al.,214 conducted a double-blind,
randomized trial of fenoldopam infusion for renal protec-
tion in 193 high-risk cardiac surgery patients, who were
randomized to receive a continuous infusion of fenoldopam,
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0.1 mg/kg/min (95 patients) or placebo (98 patients) for
24 hours. AKI was defined as a postoperative SCr level of
X2mg/dl (X177 mmol/l) with an increase in SCr level of
X0.7mg/dl (X61.9 mmol/l) from preoperative to maximum
postoperative values. AKI developed in 12 of 95 (12.6%)
patients receiving fenoldopam and in 27 of 98 (27.6%)
patients receiving placebo (P¼ 0.02), and RRTwas started in
0 of 95 and 8 of 98 (8.2%) patients, respectively (P¼ 0.004).
These results suggested that a 24-hour infusion of
0.1 mg/kg/min of fenoldopam prevented AKI in a high-risk
population undergoing cardiac surgery. A meta-analysis of
1059 patients in 13 studies that included this trial found that
fenoldopam reduces the need for RRT and in-hospital death
in cardiovascular surgery patients.215 However, the pooled
studies included both prophylactic and early therapeutic
studies, as well as propensity-adjusted case-matched studies
(rather than purely randomized trials). A 1000-patient RCT
of fenoldopam to prevent the need for RRT after cardiac
surgery is currently underway (ClinicalTrials.gov identifier:
NCT00621790); meanwhile, this remains an unproven
indication for fenoldopam therapy.
Finally, Morelli et al.,216 in a prospective, double-blind
trial, randomized 300 septic patients without renal dysfunc-
tion to receive infusions of fenoldopam (0.09 mg/kg/min)
and compared these individuals to a placebo group; the
treatment continued as long as the patient was in the ICU.
The fenoldopam group had a significantly lower rate of AKI
(29 vs. 51 patients, P¼ 0.006; OR of 0.47, P¼ 0.005), and
shorter ICU stays, without any increase in complications. The
incidence of severe AKI, dialysis, and death were not different
between the groups. This study requires a larger confirmatory
trial, which should be powered to test effectiveness in
improving dialysis-free survival.
Emerging data from experimental AKI models suggest
that fenoldopam may have multiple protective effects in AKI,
including anti-inflammatory effects independent of any vaso-
dilatory action.217,218 Further large studies will be required
to determine if fenoldopam is an effective renoprotec-
tive agent.213,219 As discussed elsewhere in this guideline
(Section 4), despite promising pilot study findings, fenoldo-
pam was ultimately found to be ineffective for the prevention
of CI-AKI,220 and as a potent antihypertensive (the only
approved indication for the drug), fenoldapam carries a
significant risk of hypotension.
Fenoldopam mesylate has also been studied for early
treatment of AKI. Tumlin et al.,221 conducted a randomized,
placebo-controlled pilot trial of low-dose fenoldopam
mesylate in ICU patients with early AKI and found no
benefit, though they did show a trend towards lower 21-day
mortality and decreased need for dialysis in fenoldopam-
treated patients (11% difference in dialysis-free survival).
In secondary analyses, fenoldopam tended to reduce the
Figure 11 | Effect of low-dose dopamine on mortality. Reprinted from Friedrich JO, Adhikari N, Herridge MS et al. Meta-analysis: low-dose
dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510–524 with permission
from American College of Physicians212; accessed http://www.annals.org/content/142/7/510.full
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primary end-point in patients without diabetes and post-
operative cardiothoracic surgery patients with early ATN.
Brienza et al.,222 conducted a prospective, multicenter,
RCT of fenoldopam therapy for early AKI in critically ill
patients. The study included hemodynamically stable adults
with renal dysfunction. This 100- subject study compared 4-
day infusions of fenoldopam (0.1 mg/kg/min) or dopamine
(2mg/kg/min); there was no placebo arm. The primary end-
point of the study was a between-group comparison of the
maximum change of SCr over time during the 4-day study
period. The peak SCr values and maximum increments
during the study did not differ between the fenoldopam and
dopamine groups; however, in the fenoldopam group at the
end of infusion, SCr had decreased by 0.29 ± 0.77mg/dl
(25.6 ± 68.1 mmol/l), a value significantly different from the
dopamine group (0.09 ± 0.94mg/dl [7.96 ± 83.1 mmol/l];
P¼ 0.05). Also, the maximum decreases of SCr levels from
study entry were significantly larger in the fenoldopam
group. There was no difference in heart rate, blood pressure,
incidence of hypotension, or urinary output (apart from a
transiently higher value within the first study day in the
dopamine group). The authors concluded that, for critically
ill patients with impaired renal function, a continuous
infusion of fenoldopam 0.1 mg/kg/min improves renal func-
tion when compared to renal-dose dopamine, without
significant adverse effects. The study has, however, a number
of deficiencies, including the lack of a true control,
unblinding of the investigators, and an unorthodox AKI
definition, among other limitations, but taken together with
other positive trends in the literature, these results add to the
discourse around fenoldopam’s use to treat early AKI in
critically ill patients. Similarly, Landoni et al.,223 in a recently
published meta-analysis found that fenoldopam decreased
the risk of requiring acute RRT and resulted in a lower all-
cause, in-hospital mortality (15.1%) compared to controls
(18.9%; OR 0.64; 95% CI 0.4–0.91), along with a non-
significant trend towards more hypotension or pressor use in
the fenoldopam group.
Our analysis revealed three suitable prophylactic studies of
adequate size and study design (Suppl Tables 5 and 6) that
reported AKI incidence in patients randomized to fenoldo-
pam (n¼ 1790) vs. placebo (n¼ 1839). The pooled RR and
95% CI was 0.96 (0.76–1.2), P¼NS. Only one study reported
mortality (8-day) in sepsis patients randomized to fenoldo-
pam (35%, n¼ 150) vs. placebo (44%, n¼ 150), with a RR of
0.79 (95% CI 0.59–1.05; P¼ 0.1).
In our analysis of the two suitable studies of fenoldopam
therapy for AKI, only one study221 reported (21-day)
mortality in critically ill patients with early AKI randomized
to fenoldopam (11/80; 13.8%) vs. placebo (n¼ 19/75, 25.3%;
P¼ 0.068) (Suppl Tables 7 and 8). The other study222
reported the change in renal function in AKI patients
randomized to fenoldopam (n¼ 50) vs. dopamine (n¼ 50),
defined by the absolute SCr change between the beginning
and end of the study drug infusion and maximum decrease
from study entry, which were significantly larger in the
fenoldopam group with a pooled RR of 0.96 (95% CI
0.76–1.2; P¼NS). These two studies reported new RRT
Figure 12 | Effect of low-dose dopamine on need for RRT. Reprinted from Friedrich JO, Adhikari N, Herridge MS et al. Meta-analysis:
low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510–524
with permission from American College of Physicians212; accessed http://www.annals.org/content/142/7/510.full
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incidence in patients with AKI randomized to fenoldopam
(n¼ 130) vs. placebo (n¼ 125). In the study by Tumlin et al.,
no difference in requirement of RRT was found (with
fenoldopam, 13 of 80 patients; 16.25%); with placebo (19 of
75 patients; 25.3%; P¼ 0.163). Requirement of RRTwas very
rare in the study of Brienza et al., and was prescribed in a
total of only five patients; three in the dopamine group and
two in fenoldopam group (P¼NS). Overall, no data from
adequately powered multicenter trials with clinically sig-
nificant end-points and adequate safety are available to
recommend fenoldopam to either prevent or treat AKI. The
guideline recommendation against using fenoldopam places a
high value on avoiding potential hypotension and harm
associated with the use of this vasodilator in high-risk
perioperative and ICU patients, and a low value on potential
benefit, which is currently only suggested by relatively low-
quality single-center trials.
RESEARCH RECOMMENDATION
K While randomized trials of fenoldopam to treat AKI in a
variety of settings (critical illness, high-risk surgery—
particular cardiac, sepsis) may be considered, the
pharmacologic strategy of renal vasodilatation has not
been successful to date and different approaches are likely
needed.
NATRIURETIC PEPTIDES FOR THE PREVENTION OR
TREATMENT OF AKI
Several natriuretic peptides are in clinical use or in
development for treatment of congestive heart failure
(CHF) or renal dysfunction, and could potentially be useful
to prevent or treat AKI.
Atrial natriuretic peptide (ANP) is a 28-amino-acid pep-
tide with diuretic, natriuretic, and vasodilatory activity.224
ANP is mainly produced in atrial myocytes, and the rate of
release from the atrium increases in response to atrial
stretch.225 Early animal studies showed that ANP decreases
preglomerular vascular resistance and increases postglomer-
ular vascular resistance, leading to increased GFR.226 It also
inhibits renal tubular sodium reabsorption. Increases in GFR
and diuresis have also been confirmed in clinical studies.227 It
could thus be expected that ANP might be useful for
treatment of AKI, and several RCTs have been conducted to
test this hypothesis.
3.5.3: We suggest not using atrial natriuretic peptide
(ANP) to prevent (2C) or treat (2B) AKI.
RATIONALE
There have been several negative studies of prophylactic ANP
therapy; for example, ANP failed in two studies to prevent
primary renal transplant dysfunction228,229 and ANP pro-
phylaxis also failed to prevent CI-AKI.230 Based on the
positive results of small clinical studies using ANP to treat
AKI, a randomized placebo-controlled trial in 504 critically
ill patients with AKI was conducted.231 Patients received 24-
hour i.v. infusion of either ANP (0.2 mg/kg/min) or placebo.
The primary outcome was dialysis-free survival for 21 days
after treatment. Despite the large size of the trial, ANP
administration had no effect on 21-day dialysis-free survival,
mortality, or change in plasma creatinine concentration. Of
note, the mean SCr at enrollment (anaritide group: 4.4mg/dl
[389 mmol/l]; placebo group: 5.0mg/dl [442 mmol/l]) in this
study confirms that intervention in this trial was extremely
late in the course of AKI. In subgroup analysis, dialysis-free
survival was higher in the treatment group for patients with
oliguria (o400ml/d; ANP 27%, placebo 7%, P¼ 0.008). A
subsequent trial in 222 patients with oliguric renal failure,
however, failed to demonstrate any benefit of ANP.232 The
dose and duration of ANP treatment and primary outcome
were the same as the previous study. The dose of ANP might
have been too high (0.2 mg/kg/min) in both studies:
hypotension (systolic blood pressure o90mm Hg) occurred
more frequently in the ANP groups of both trials (in the first
study, 46% vs. 18%, Po0.001; and in the second study, 97%
vs. 58%, Po0.001), and this may have negated any potential
benefit of renal vasodilation in these patients. In addition to
an excessive dose, the failure of these large studies has also
been attributed in subsequent analyses to the late initiation of
the drug to patients with severe AKI and an inadequate
duration of infusion (only 24 hours).
A promising, but underpowered, study of ANP to treat
AKI immediately following cardiac surgery showed a
decreased rate of postoperative RRT compared to placebo-
treated patients.233 In this study, Sward et al. randomized 61
patients with AKI following cardiac surgery (defined as a SCr
increase X50% from a baseline o1.8mg/dl [o159 mmol/l])
to receive infusion of ANP or placebo until the SCr decreased
below the baseline value at enrollment, the patient died, or
one of four prespecified dialysis criteria was reached. Of note,
all patients received infusions of furosemide (20–40mg/h)
and oliguria, defined as a urine output p0.5ml/kg/h for 3
hours, was an exclusion criterion and an automatic dialysis
indication. The primary end-point was the rate of dialysis
within 21 days of enrollment. CrCl was significantly higher
on the third study day in ANP-treated subjects (P¼ 0.04).
Using prespecified dialysis criteria, 21% of patients in the
ANP group and 47% in the placebo group were dialyzed
within 21 days (hazard ratio [HR] 0.28; 95% CI 0.10–0.73;
P¼ 0.009). The combined secondary end-point of death-or-
dialysis was similarly improved in the ANP group (28%)
compared to placebo (57%; HR 0.35; 95% CI 0.14–0.82;
P¼ 0.017). The incidence of hypotension during the first 24
hours was 59% in the ANP group and 52% in controls
(P¼NS).
It is intriguing to speculate on the potential reasons for the
positive outcome of this trial, compared to larger prior
studies of ANP for AKI prevention and therapy. Apart from
the possibility that this is a false-positive, underpowered
study, possible explanations include the use of ANP earlier in
the course of AKI (the mean SCr in the prior ANP studies
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was much higher), and at lower doses (50 ng/kg/min vs.
200 ng/kg/min) that avoided the significant rate of hypoten-
sion observed in prior trials. The use of prespecified dialysis
criteria was another strength of this trial. More recently,
Sward et al.,234 compared the renal hemodynamic effects
of ANP and furosemide in 19 mechanically ventilated
post–cardiac surgery patients with normal renal function,
measuring renal blood flow, GFR, and renal oxygen
extraction. ANP infusion (25–50 ng/kg/min) increased GFR,
filtration fraction, fractional excretion of sodium, and urine
output, accompanied by a 9% increase in tubular sodium
absorption and a 26% increase in renal oxygen consumption.
Furosemide infusion (0.5mg/kg/h) increased urine output
10-fold and fractional excretion of sodium 15-fold, while
decreasing tubular sodium absorption by 28% and lowering
renal oxygen consumption by 23%. Furosemide also lowered
GFR by 12% and filtration fraction by 7%. Thus, although
the balance of renal hemodynamic and tubular effects of the
two drugs appears to favor furosemide for improving renal
oxygen delivery-consumption balance, ANP is more likely to
acutely improve GFR. One might speculate that the use of
furosemide infusion in all of the subjects in the successful
ANP trial may have provided an important protection
against renal ischemia by reducing tubular sodium absorp-
tion and associated oxygen consumption, despite an increase
in GFR in the ANP group. A larger prospective trial of ANP
to improve dialysis-free survival in this setting is required,
perhaps with and without furosemide infusion.
Pooled analysis of 11 studies involving 818 participants in
the prevention cohort showed a trend toward reduction in
the need for RRT in the ANP group (OR 0.45; 95% CI
0.21–0.99; P¼ 0.05). Restricting the analysis to studies that
used low-dose ANP preparations did not change the overall
effect for this outcome. There was no significant difference
noted between the ANP and control groups for mortality in
the prevention category (OR 0.67; 95% CI 0.19–2.35;
P¼ 0.53), and this effect was unchanged by restricting the
analysis to studies that used low-dose ANP preparations.
However, these studies were generally of poor quality, several
without reported baseline SCr values or clear definitions of
AKI or RRT indications (Suppl Tables 10 and 11), and only
one was of adequate quality.
Nigwekar et al., recently conducted a systematic review
and meta-analysis of ANP for management of AKI.235 They
found 19 relevant studies, among which 11 studies were for
prevention and eight were for treatment of AKI. Pooled
analysis of the eight treatment studies, involving 1043
participants, did not show significant difference for RRT
requirement between the ANP and control groups (OR 0.59;
95% CI 0.32–1.08; P¼ 0.12). There was also no significant
difference for mortality (OR 1.01; 95% CI 0.72–1.43;
P¼ 0.89). However, low-dose ANP preparations were
associated with significant reduction in RRT requirement
(OR 0.34; 95% CI 0.12–0.96; P¼ 0.04). The incidence of
hypotension was not different between the ANP and control
groups for low-dose studies (OR 1.55; 95% CI 0.84–2.87),
whereas it was significantly higher in the ANP group in the
high-dose ANP studies (OR 4.13; 95% CI 1.38–12.41).
Finally, a pooled analysis of studies that examined oliguric
AKI did not show any significant benefit from ANP for RRT
requirement (OR 0.46; 95% CI 0.19–1.12; P¼ 0.09) or
mortality (OR 0.94; 95% CI 0.62–1.43; P¼ 0.79). Only two
of the treatment studies included in the Nigwekar analy-
sis231,232 were of adequate size and quality to meet the criteria
for our systematic review (Suppl Tables 12 and 13), which
found no significant inconsistencies in the findings of both
trials that (combined) included 720 subjects (351 treated
with ANP) (Suppl Table 12). Thus, although subset analyses
separating low-dose from high-dose ANP trials suggest
potential benefits, the preponderance of the literature
suggests no benefit of ANP therapy for AKI. Therefore, the
Work Group suggests that these agents not be used to prevent
or treat AKI. This conclusion is based on placing a high value
on avoiding potential hypotension and harm associated with
the use of a vasodilator in high-risk perioperative and ICU
patients, and a low value on potential benefit which is
supported by relatively low-quality evidence from retro-
spective subset analyses from negative multicenter trials.
Urodilatin is another natriuretic peptide that is produced
by renal tubular cells, and was found to have the same renal
hemodynamic effect as ANP without systemic hypotensive
effects.236 Limited data suggest that urodilatin improves the
course of established postoperative AKI.237 Fifty-one patients
who received orthotopic heart transplants received urodilatin
(6–20 ng/kg/min) up to 96 hours postoperatively. AKI
occurred in 6% of these patients, compared to 20% in a
historical control group that did not receive urodilatin.237
However, in another small, placebo-controlled study of 24
patients who underwent orthotopic heart transplants, the
incidence of AKI was unchanged,238 although duration of
hemofiltration (HF) was significantly shorter and the
frequency of intermittent hemodialysis (IHD) less in those
who received urodilatin. Taken together, these data suggest
that natriuretic peptides may have a role in the therapy of
early AKI following cardiac surgery, but further prospective
trials are needed to confirm this potential indication.
Nesiritide (brain natriuretic peptide) is the latest natriuretic
peptide introduced for clinical use, and is approved by the
Food and Drug Administration (FDA) only for the therapy
of acute, decompensated CHF. Meta-analysis of outcome
data from these and some other nesiritide CHF trials
has generated some controversy.239–241 Sackner-Bernstein
et al.,239 analyzed mortality data from 12 randomized trials;
in three trials that provided 30-day mortality data, they
found a trend towards an increased risk of death in nesiritide-
treated subjects. In another meta-analysis of five randomized
trials that included 1269 subjects,240 the same investi-
gators also found that there was a relationship between
nesiritide use and worsening renal function, defined as
a SCr increase 40.5mg/dl (444.2 mmol/l). Nesiritide doses
p0.03 mg/kg/min significantly increased the risk of renal
dysfunction compared to non–inotrope-based controls or
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compared to all control groups (including inotropes). Even
at doses p0.015 mg/kg/min, nesiritide was associated with
increased renal dysfunction compared to controls. There was
no difference in dialysis rates between the groups. Another
retrospective study determined independent risk factors for
60-day mortality by multivariate analysis in a cohort of 682
elderly heart-failure patients treated with nesiritide vs. those
who were not.242 When patients were stratified according to
nesiritide usage, AKI emerged as an independent risk factor
for mortality only among patients who received the drug.
Strikingly, among these heart-failure patients who developed
AKI, nesiritide usage emerged as the only independent
predictor of mortality.
The manufacturers of nesiritide convened an expert panel,
which concluded that further trial data are needed to discern
the effects of nesiritide therapy on renal function and survival
in patients with decompensated CHF. The panel also re-
emphasized that the indication for nesiritide therapy is acute
decompensated CHF, not chronic intermittent therapy or
other uses, and in particular noted that the drug should not
be used to improve renal function or in place of diuretic
therapy in CHF patients, as there is no proof of the utility of
the drug for these purposes. A 7000-patient multicenter RCT
in acute decompensated heart failure is currently in progress
to determine the clinical effectiveness of nesiritide therapy for
acute decompensated heart failure (the Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated Heart
Failure; Clinicaltrials.gov identifier NCT00475852). Mean-
while, nesiritide is approved for treatment of symptomatic
acute decompensated heart failure.
Uncontrolled studies using nesiritide for cardiovascular
support of patients with CHF undergoing cardiac surgery
have suggested beneficial effects on renal function. Mentzer
et al.,243 conducted a 303-patient, multicenter, randomized,
double-blind trial of a 24- to 96-hour infusion of 0.01 mg/kg/
min of nesiritide vs. placebo in patients with chronic left
ventricular dysfunction (ejection fraction p40%) under-
going cardiac surgery using cardiopulmonary bypass. The
Nesiritide Administered Peri-Anesthesia in Patients Under-
going Cardiac Surgery trial was an exploratory, safety-
oriented study with five primary end-points, including three
renal end-points and two hemodynamic end-points. There
were no significant differences between the groups in base-
line patient characteristics; SCr values were B1.1mg/dl
(97.2 mmol/l), with eGFR B80ml/min per 1.73 m2. The
mean duration of study drug infusion was B40 hours in
both groups. Perioperative renal function quantified by the
three renal primary end-points was better in the nesiritide
group (peak SCr increase of 0.15mg/dl [13.3 mmol/l] vs.
placebo group 0.34mg/dl [30.1 mmol/l]; Po0.001; eGFR
decrease of 10.2ml/min per 1.73 m2 vs. placebo 17.8ml/
min per 1.73 m2, P¼ 0.001; initial 24-hour urinary output
2.9± 1.2 l vs. placebo 2.3± 1 l; Po0.001). The RR of AKI in
the nesiritide group compared to placebo was 0.58
(0.27–1.21); the 180-day mortality was also reduced in the
nesiritide group (RR 0.48 [0.22–1.05]; P¼ 0.046) (Suppl
Table 9). These trends were more pronounced in the small,
62-patient subset with preoperative SCr values 41.2mg/dl
(4106 mmol/l). Although SCr increased postoperatively in
both groups, it returned to baseline within 12 hours in the
nesiritide group, and remained elevated throughout hospi-
talization in the placebo group. Use of vasoactive drugs and
hemodynamic parameters did not differ significantly between
the groups. Adverse events also were similar between the
groups, as was 30-day and 180-day mortality (although
capture of mortality data was incomplete). Thus, it appears
that administration of nesiritide infusion during and after
cardiac surgery with cardiopulmonary bypass in patients
with preoperative left ventricular dysfunction has favorable
short-term effects on renal function, with short-term adverse
effects comparable to placebo infusion; however, as men-
tioned earlier, this is not an FDA-approved indication for this
drug. It is interesting to speculate that, based upon these
results, any renoprotective effect of this vasoactive drug
during and after cardiopulmonary bypass is not mediated by
effects on systemic perfusion (similar in both groups), but
rather suggesting an effect on regional perfusion or a
pleiotropic phenomenon. Unfortunately, these promising
pilot study findings have not been followed up with a
confirmatory prospective clinical trial.
A prospective, randomized clinical trial (the Nesiritide
Study), found no benefit of nesiritide for 21-day dialysis and/
or death in patients undergoing high-risk cardiovascular
surgery.244 However, the study did demonstrate that the
prophylactic use of nesiritide was associated with reduced
incidence of AKI, the latter defined by the AKIN Group, in
the immediate postoperative period (nesiritide 6.6% vs.
placebo 28.5%, P¼ 0.004). Recently, Lingegowda et al.245
investigated whether the observed renal benefits of nesiritide
had any long-term impact on cumulative patient survival and
renal outcomes. Data on all 94 patients from the Nesiritide
Study were obtained with a mean follow-up period of 20.8±
10.4 months. No differences in cumulative survival between
the groups were noted, but patients with in-hospital
incidence of AKI had a higher rate of mortality than those
with no AKI (41.4% vs. 10.7%; P¼ 0.002). It seemed, thus,
that the possible renoprotection provided by nesiritide in the
immediate postoperative period was not associated with
improved long-term survival in patients undergoing high-
risk cardiovascular surgery.
In summary, although evidence from a variety of small
studies suggests the potential for therapy with natriuretic
peptides to be useful for the prevention or treatment of AKI
in a variety of settings, there are no definitive trials to support
the use of ANP, BNP, or nesiritide for these purposes. Thus,
the Work Group suggests that these agents not be used for
prevention or treatment of AKI.
RESEARCH RECOMMENDATION
K We recommend further trials of ANP at doses below
0.1 mg/kg/min, for the prevention or treatment of AKI.
There is a possibility that ANP might be effective if it is
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given at a lower dose (0.01–0.05 mg/kg/min) in patients
prophylactically or with early AKI, and during a longer
period than in previous large studies.
SUPPLEMENTARY MATERIAL
Supplementary Table 4: Summary table of RCTs examining the effect
of dopamine vs. placebo for the treatment of AKI.
Supplementary Table 5: Evidence profile of RCTs examining fenoldo-
pam vs. control for the prevention of AKI.
Supplementary Table 6: Summary table of RCTs examining the effect
of fenoldopam for the prevention of AKI.
Supplementary Table 7: Evidence profile of RCTs of fenoldopam vs.
placebo for the treatment of AKI.
Supplementary Table 8: Summary table of RCTs of examining the
effect of fenoldopam for the treatment of AKI.
Supplementary Table 9: Summary table of RCTs of nesiritide vs. control
for the prevention of AKI.
Supplementary Table 10: Evidence profile of RCTs examining anaritide
vs. control for the prevention of AKI.
Supplementary Table 11: Summary table of RCTs examining the effect
of anaritide vs. control for the prevention of AKI.
Supplementary Table 12: Evidence profile of RCTs examining anaritide
vs. placebo for the treatment of AKI.
Supplementary Table 13: Summary table of RCTs examining the effect
of ANP vs. placebo for the treatment of AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 3.6: Growth factor intervention
Recovery from AKI involves increased expression of various
growth factors acting via autocrine, paracrine, and endocrine
mechanisms. The advent of recombinant growth factors has
stimulated research exploring their therapeutic potential
in AKI. Experimental studies have yielded promising results
with individual growth factors246 including insulin-like
growth factor-1 (IGF-1), hepatic growth factor, and, more
recently, erythropoietin. The physiological basis for the use of
erythropoietin in the prevention of AKI has recently been
described.247
3.6.1: We recommend not using recombinant human
(rh)IGF-1 to prevent or treat AKI. (1B)
RATIONALE
IGF-1 is a peptide with renal vasodilatory, mitogenic and
anabolic properties. rhIGF-1 has been demonstrated to
accelerate the recovery of renal function in several animal
models of AKI.248–251 Three double-blind, placebo-controlled
RCTs have addressed the usefulness of IGF-1 in adults
with imminent or established AKI.252–254 Franklin et al.,252
administered rhIGF-1 every 12 hours for 3 days post-
operatively to 54 patients undergoing abdominal aortic
surgery. While no patient developed ARF, a smaller propor-
tion of IGF-1–treated patients showed a decline in GFR as
compared to the placebo group (22% vs. 33%). Hladunewich
et al.,254 administered rhIGF-1 or placebo in 43 patients
undergoing cadaveric renal transplantation at high risk of
delayed graft function. Treatment was started within 5 hours
of transplantation and continued for 6 days. On day 7,
neither inulin clearance, nor urine flow or fractional sodium
excretion differed between the treatment arms, nor did
the nadir SCr after 6 weeks or the proportion of patients
require post-transplantation dialysis. Hirschberg et al.,253
treated 72 patients suffering from AKI mainly due to sepsis or
hemodynamic shock with either rhIGF-1 or placebo for a
mean of 10.6 days. No differences were observed with respect
to changes in GFR, urine output, need for RRT, and
mortality. Hence, despite its therapeutic efficacy in various
animal models of ARF, rhIGF-1 largely failed to prevent
or accelerate recovery from established AKI in humans.
In addition, the high cost of this treatment should be
mentioned.
Based on an analysis of the three RCTs with rhIGF-1 that
are currently available and which were overall negative or at
least equivocal, and considering that there is no benefit and
the concern over potential harm and cost associated with this
drug, the Work Group recommends against its use in patients
with AKI.
Erythropoietin
A small pilot trial evaluated the effectiveness of erythro-
poietin in the prevention of AKI after elective coronary
artery bypass graft.255 Patients received either 300 U/kg of
erythropoietin or saline i.v. before surgery. AKI was defined
as a 50% increase in SCr levels over baseline within the
first five postoperative days. Of 71 patients, 13 developed
postoperative AKI: three of the 36 patients in the erythro-
poietin group (8%) and 10 of the 35 patients in the placebo
group (29%; P¼ 0.035). The increase in postoperative SCr
concentration and the decline in postoperative eGFR were
significantly lower in the erythropoietin group than in the
placebo group.
More recently, Endre et al.,256 performed a pros-
pective randomized trial with erythropoietin in the primary
prevention of AKI in ICU patients at risk for AKI (Suppl
Table 14). As a guide for choosing the patients for treatment
the urinary levels of two biomarkers, the proximal tubular
brush border enzymes c-glutamyl transpeptidase and alkaline
phosphatase were measured. Randomization to either
placebo or two doses of erythropoietin was triggered by an
increase in the biomarker concentration product to levels
above 46.3. The primary outcome was the relative average
SCr increase from baseline over 4–7 days. The triggering
biomarker concentration product selected patients with
more severe illness and at greater risk of AKI, dialysis,
or death; however, the urinary marker elevations were
transient. The use of the biomarkers allowed randomization
within an average of 3.5 hours of a positive sample. There
was no difference in the incidence of erythropoietin-specific
adverse events; however, there was also no difference
in the primary outcome between the placebo and treatment
groups.
RESEARCH RECOMMENDATION
K Recent animal studies suggest a potential clinical benefit
of erythropoietin in AKI. In various rodent models of
AKI, erythropoietin consistently improved functional
recovery. The renoprotective action of erythropoietin
may be related to pleomorphic properties including
antiapoptotic and antioxidative effects, stimulation of cell
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proliferation, and stem-cell mobilization.247 Although
one recent RCT in the prevention of human AKI was
negative, the usefulness of erythropoietin in human AKI
should be further tested in RCTs.
SUPPLEMENTARY MATERIAL
Supplementary Table 14: Summary table of RCTs examining the effect
of erythropoietin vs. placebo for the prevention of AKI.
Supplementary material is linked to the online version of the paper at
http://www.kdigo.org/clinical_practice_guidelines/AKI.php
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Chapter 3.7: Adenosine receptor antagonists
The activation of tubuloglomerular feedback in response to
elevated luminal chloride concentrations in the distal renal
tubules is an early event in ischemic AKI. Adenosine released
as part of the tubuloglomerular feedback loop binds to
glomerular adenosine A1 receptor, causing vasoconstriction
of the afferent arteriole, decreased renal blood flow and GFR,
and sodium and water retention. This well-known role of
adenosine in this phenomenon has stimulated a body of
research seeking to prevent or treat AKI with adenosine
receptor antagonists, primarily in three clinical syndromes
with increased risk of AKI: perinatal asphyxia, radiocontrast
exposure, and cardiorenal syndrome. Theophylline is a
nonselective adenosine receptor antagonist.
3.7.1: We suggest that a single dose of theophylline may
be given in neonates with severe perinatal asphyxia,
who are at high risk of AKI. (2B)
RATIONALE
AKI occurs in 60% of neonates suffering from perinatal
asphyxia.257 Experimental studies indicated an important role
of adenosine-mediated vasoconstriction in neonatal kidneys
exposed to normocapnic hypoxemia.258 A potential renoprotec-
tive effect of theophylline in perinatal asphyxia has been assessed
in three randomized, placebo-controlled clinical trials,259–261
including a total of 171 term neonates. Theophylline was
uniformly administered in the first hour of life as a single i.v.
bolus at a dose of 5mg/kg259,261 or 8mg/kg.260 The three studies
all observed significantly higher GFR, higher urine output with
more negative fluid balance, and lower urinary b2-microglobu-
lin excretion, with theophylline as compared to placebo during
the first 3–5 days of life. In each study, theophylline treatment
was associated with a significantly reduced risk of severe renal
dysfunction (17–25% vs. 55–60% in placebo group, RR
0.3–0.41). The beneficial effect was selective for kidney function,
whereas the incidence of central nervous system, cardiac,
pulmonary, and gastrointestinal complications was unaltered.
Patient survival was not affected by treatment. In line with these
studies in mature neonates, a similar improvement of GFR and
urine output was observed during the first 2 days of life by
administration of 1mg/kg theophylline vs. placebo in 50 very
preterm neonates with respiratory distress syndrome.262 The
further evolution of renal function was followed throughout the
first year of life by Bhat et al.,260 who found equally normal
glomerular and tubular function in both groups from 6 weeks of
age onward. Hence, while theophylline clearly improves renal
function in the first week of life in postasphyctic neonates, the
overall benefit from this intervention in neonatal intensive care
is less evident in view of the complete long-term recovery of
renal function in the placebo-treated controls and the absence
of an effect on patient survival.
In recent years, the advent of selective adenosine A1
receptor antagonists has prompted the conduct of some
interesting clinical trials, which to date have focused on the
prevention and treatment of cardiorenal syndrome. In a
double-blind placebo-controlled trial of 63 patients with
CHF, single doses of the adenosine A1 antagonist BG9719
had a marked stimulatory effect on diuresis and increased
GFR.263 When coadministered with furosemide, BG9719
showed a synergistic diuretic effect and prevented the
decrease in GFR associated with the loop diuretic.
Rolofylline, another adenosine A1 receptor antagonist,
was tested in two double-blind placebo-controlled RCTs in
patients with acute decompensated heart failure. In the first
study, rolofylline or placebo was administered either
concomitantly with furosemide for 3 days (146 patients), or
as a single infusion in 35 diuretic resistant patients.264 In both
substudies, rolofylline improved urine output and CrCl
compared to placebo. The second trial involved 301 patients
hospitalized for acute heart failure with renal impairment
who received either placebo or one of three doses of
rolofylline for 3 days.265 Rolofylline administration dose-
dependently attenuated the rise in SCr observed in the
placebo group within 14 days, and tended to reduce 60-day
mortality or readmission for cardiovascular or renal causes.
Three pivotal phase III trials in a total of 2500 patients
were recently completed, aiming to corroborate the reno-
protective effects of rolofylline in patients with cardiorenal
syndrome, and to establish drug safety. The final results of the
PROTECT trial have recently been published.266 Rolofylline,
as compared to placebo, did not provide a benefit with
respect to the three primary end-points: survival, heart-
failure status, and changes in renal function. Persistent renal
impairment developed in 15.0% of patients in the rolofylline
group and in 13.7% of patients in the placebo group
(P¼ 0.44). By 60 days, death or readmission for cardiovas-
cular or renal causes had occurred in similar proportions of
patients assigned to rolofylline and placebo (30.7% and
31.9%, respectively; P¼ 0.86). Adverse-event rates were
similar overall; however, only patients in the rolofylline
group had seizures, a known potential adverse effect of
A1-receptor antagonists. Thus, rolofylline does not appear to
be effective for treatment of cardiorenal AKI.
RESEARCH RECOMMENDATION
K It appears that if there are benefits of using adeno-
sine receptor antagonists to decrease tubuloglomerular
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feedback-mediated vasoconstriction and increase renal
blood flow and GFR in AKI, they may be limited to very
specific populations (e. g., asphyctic neonates). These
benefits must be balanced against potential adverse
drug effects: both renal (increased renal blood flow and
distal salt delivery might harmfully increase tubular
oxygen consumption in the presence of ATN), and
nonrenal (lower seizure threshold). Thus, further studies
are still needed to clarify the role for theophylline in
neonates.
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Chapter 3.8: Prevention of aminoglycoside- and
amphotericin-related AKI
AMINOGLYCOSIDE NEPHROTOXICITY
Aminoglycoside antimicrobial agents are highly potent,
bactericidal antibiotics effective against multiple Gram-
negative, and selected Gram-positive bacterial pathogens
when administered with beta-lactams and other cell-wall
active antimicrobial agents.267–269 Progressive antimicrobial
resistance to other antimicrobial agents and lack of new
alternatives to aminoglycoside antibiotics have caused a
recent increase in their use. Aminoglycosides have many
favorable attributes, including their remarkable stability,
predictable pharmacokinetics, low incidence of immuno-
logically mediated side-effects, and lack of hematologic or
hepatic toxicity. Nephrotoxicity, and to a lesser degree
ototoxicity and neuromuscular blockade, continue to be
the major dose-limiting toxicities of the aminoglycosides.
Careful dosing and therapeutic drug monitoring of amino-
glycosides using pharmacokinetic and pharmacodynamic
principles can mitigate the risk of AKI with these clinically
useful, yet nephrotoxic antibiotics.270 A number of meta-
analyses and treatment guidelines have been published
recently indicating that the risk of AKI attributable to
aminoglycosides is sufficiently frequent that they should no
longer be added to other standard antimicrobial agents for
the empirical or directed treatment of a number of severe
Gram-positive or Gram-negative bacterial infections.271–276
The intrinsic risk of AKI with the administration of
aminoglycosides has led some authors to call for elimination
of aminoglycosides as a therapeutic option in current clinical
management of infectious diseases.277 The anticipated demise
of aminoglycosides from our therapeutic armamentarium
has not occurred, however, in light of recent developments
with progressive antimicrobial resistance to beta-lactams,
quinolones, and a number of other classes of antimicrobial
agents.
3.8.1: We suggest not using aminoglycosides for the treat-
ment of infections unless no suitable, less nephro-
toxic, therapeutic alternatives are available. (2A)
RATIONALE
Aminoglycosides exhibit a number of favorable pharmaco-
kinetic and pharmacodynamic advantages, but a major dose-
limiting toxicity of the aminoglycosides remains the risk
of drug-induced AKI.270 The risk of AKI attributable to
aminoglycosides is sufficiently high (up to 25% in some
series, depending upon the definition of AKI used and the
population studied)271–276,278 that they should no longer be
used for standard empirical or directed treatment, unless no
other suitable alternatives exist. The intrinsic risk of AKI with
the administration of aminoglycosides has led some authors
to recommend the elimination of aminoglycosides as a
clinical treatment option.277 Certainly their use should be
restricted to treat severe infections where aminoglycosides are
the best, or only, therapeutic option.
Aminoglycosides should be used for as short a period of
time as possible. Repeated administration of aminoglycosides
over several days or weeks can result in accumulation of
aminoglycosides within the renal interstitium and within
the tubular epithelial cells.279 This can result in a higher
incidence of nephrotoxicity with repeated exposure to
aminoglycosides over time. Older patients (465 years),
patients with pre-existing renal dysfunction, and septic
patients with intravascular volume depletion and rapid
alterations in fluid dynamics may be at greater risk for
aminoglycoside nephrotoxicity. Other risk factors for ami-
noglycoside-induced AKI are diabetes mellitus, concomitant
use of other nephrotoxic drugs, prolonged use, excessive
blood levels, or repeated exposure to separate courses of
aminoglycoside therapy over a short time interval.267–279
3.8.2: We suggest that, in patients with normal kidney
function in steady state, aminoglycosides are
administered as a single dose daily rather than
multiple-dose daily treatment regimens. (2B)
RATIONALE
Aminoglycoside demonstrates concentration-dependent bac-
tericidal activity, with a prolonged ‘‘postantibiotic effect’’,
thereby permitting extended interval dosing in an effort to
optimize efficacy and minimize toxicity. This dosing strategy
and a number of other measures to limit aminoglycoside
uptake in renal tubular cells, prevent apoptosis, limit oxygen
injury, and protect mitochondrial function have all been
recommended to minimize the risk of AKI and preserve
the therapeutic value of these important antimicrobial
agents.280–296 Single-dose daily or extended-interval dosing
of aminoglycosides offer a number of theoretical and
practical advantages to maintain antimicrobial activity while
limiting possible nephrotoxicity. This convenient and
inexpensive aminoglycoside dosing strategy has been widely
adopted at many centers when using this potentially toxic, yet
highly effective, class of antibiotics.
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When feasible in patients with normal and stable kidney
function, once-daily (often referred to as extended-interval)
dosing of aminoglycosides should be used to limit amino-
glycoside nephrotoxicity. The pharmacokinetic and pharma-
codynamic properties of aminoglycosides favor high dosing
strategies with extended intervals between doses. The key
therapeutic parameter for efficacy is peak blood level divided
by minimum inhibitory concentration (MIC) of the infecting
organism (Cmax/MIC) in an effort to obtain 410-fold
Cmax/MIC. Aminoglycosides induce a prolonged postanti-
biotic effect (inhibition of bacterial growth after blood levels
have fallen below the MIC of the organism). The length of the
postantibiotic effect is directly related to the peak blood
levels. These pharmacokinetic/pharmacodynamic parameters
make single-dose daily strategies an attractive option when
using aminoglycosides.
The nephrotoxicity of aminoglycosides has been very well
studied280–282,284–293,295,296 and is primarily related to uptake
of aminoglycosides through a receptor known as megalin,
expressed on epithelial cells along the proximal convoluted
tubule.293 Aminoglycosides are concentrated in the proximal
convoluted tubules, where they bind avidly to polyanionic,
phospholipid-containing membranes. Aminoglycosides in-
duce myeloid body formation, impair protein synthesis,
degrade mitochondrial function, and culminate in apoptosis
and eventual necrosis of renal tubular epithelial cells. Direct
glomerular injury can occur288 but is usually a secondary
consequence of aminoglycoside-induced tubular impairment.
As the receptor uptake of aminoglycosides is saturable, high-
level intermittent doses of aminoglycosides actually reduced
the daily uptake and accumulation of aminoglycosides when
compared to multiple-daily dosing strategies. This should
limit the risk of nephrotoxicity, at least in principle.
The potential efficacy of single-dose daily regimens (or
other extended dosing treatment programs) of aminoglyco-
sides vs. multiple-daily dosing strategies has been extensively
studied in numerous controlled and uncontrolled clinical
studies over many years297–308, and the subject has been the
focus of a number of formal meta-analyses.309–314 These
investigations include pediatric populations, elderly popula-
tions, empirical therapy, targeted therapy, treatment directed
towards Gram-negative bacterial pathogens and Gram-
positive bacterial pathogens.
The cumulative results of this evidence-based review and
numerous meta-analyses indicate that once-daily dosing
strategies generally tend to result in less AKI when compared
to multiple-dose dosing strategies, although the benefit
accrued by the single-daily dose strategy is modest and
inconsistent across a number of these studies. For this reason,
a level 2 recommendation is suggested in support of the
use of single-daily dose strategies over multiple-dose daily
strategies. It should be noted that multiple-daily dosing
strategies continue to be the standard of care for enterococcal
endocarditis; no detailed, randomized trials have been
reported comparing single-daily vs. multiple-daily regimens
for enterococcal endocarditis.272,315–317
The use of single-daily dosing of aminoglycosides is
generally well-tolerated but bolus infusions of aminoglyco-
sides should be avoided. The high-dose, once-daily amino-
glycoside regimens should be administered over 60minutes
to avoid untoward events such as neuromuscular blockade.
This recommendation is particularly important when
patients are receiving other potential neuromuscular block-
ing agents, or have underlying disorders affecting neuro-
muscular transmission (e.g., myasthenia gravis).
3.8.3: We recommend monitoring aminoglycoside drug
levels when treatment with multiple daily dosing is
used for more than 24 hours. (1A)
RATIONALE
Therapeutic drug monitoring has been the standard of care
when administering aminoglycosides for many years. Amino-
glycoside levels are variable among individuals, and subtle
changes in the volume distribution, renal blood flow, and
filtration rate can affect renal handling of aminoglycosides
and alter the risk of nephrotoxicity. For these reasons,
therapeutic drug monitoring, in combination with or
independent from, single-dose daily treatment regimens is
recommended.318–321 When using therapeutic drug monitor-
ing in single-dose or extended-dose treatment strategies, the
Cmax should be at least 10-fold greater than the MIC of the
infecting microorganism. This Cmin (trough level) should be
undetectable by 18–24 hours to limit accumulation of
aminoglycosides in renal tubular cells and to minimize the
risk of AKI. The usual dosing strategy for once-daily
aminoglycosides is 5mg/kg/d for gentamicin and tobramycin
(with normal renal function); 6mg/kg/d for netilmicin; and
15mg/kg/d for amikacin. The multiple-dose daily regimen
for gentamicin and tobramycin is usually 1.7mg/kg every
8 hours with peak blood levels at 8± 2 mg/ml (17±4 mmol/l)
and trough of 1–2 mg/ml (2–4 mmol/l). Amikacin levels with
the multiple-dose daily dosing strategy should be a peak
of 20±5 mg/ml (34±9 mmol/l) and a trough of 5–8 mg/ml
(9–14 mmol/l). We recommend therapeutic drug monitoring
when using prolonged courses of aminoglycosides to limit
the risk of nephrotoxicity when using multiple-daily dosing,
and suggest therapeutic drug monitoring when using single-
daily dosing strategies.
3.8.4: We suggest monitoring aminoglycoside drug levels
when treatment with single-daily dosing is used for
more than 48 hours. (2C)
RATIONALE
The timing of measurement of peak doses of aminoglycosides
with single-daily dosing strategies is not standardized and
remains somewhat controversial. Some investigators do not
measure therapeutic drug levels at all in patients receiving
this dosing strategy. Others recommend at least a single peak
measurement to ensure that the blood levels are 10-fold
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greater than the MIC of the infecting organism. Many
investigators recommend at least one or at least a weekly
Cmin level obtained at either 12, 18, or 24 hours after the
aminoglycoside dose.267–270 The Cmin level should be below
the limits of detection of the assay (o1 mg/ml) at these time
intervals.
Measuring aminoglycoside levels with multiple-daily
dosing strategies have been standardized for Cmax to be
obtained 30minutes after a 30-minute infusion, and Cmin
right before the next dose for trough levels. The aminoglyco-
sides should be administered in patients who are volume-
replete; volume depletion increases the risk of nephrotoxicity
in experimental studies and is suggested in clinical studies.
Additionally, potassium repletion has been shown experi-
mentally and clinically to diminish the risk of AKI related to
aminoglycoside administration.
Single-dose daily regimens are difficult to apply in patients
with pre-existing kidney disease, and patients with vacillating
eGFR and hemodynamics, such as critically ill patients in the
ICU setting. The changing pharmacokinetics and pharma-
codynamics of antibiotics in general and aminoglycosides in
particular, in the critically ill patient, are such that the
avoidance of single-daily dosing and application of frequent
therapeutic drug monitoring is indicated.322
3.8.5: We suggest using topical or local applications of
aminoglycosides (e.g., respiratory aerosols, instilled
antibiotic beads), rather than i.v. application, when
feasible and suitable. (2B)
RATIONALE
Local instillation of aminoglycosides for a variety of
indications is gaining more widespread use in a selected set
of clinical situations where aminoglycoside levels can be
concentrated at specific tissue sites. The use of aminoglyco-
side-loaded beads for the prevention and treatment of bone
and joint infections have become commonplace as a strategy
to limit nephrotoxicity, while providing antimicrobial
activity of aminoglycosides at the tissue level.323 Local
concentrations of aminoglycoside are achieved for prolonged
periods when administered by this route. Aminoglycoside
aerosol delivery systems are now in use to provide high
intrapulmonary antibiotic levels with minimal systemic and
kidney concentrations of the antibiotic. This strategy has
been used successfully in cystic fibrosis patients for the
management of difficult-to-treat Gram-negative bacillary
pneumonia.324,325 However, significant nephrotoxicity with
the use of inhaled tobramycin has been described in at least
two cases.326,327
RESEARCH RECOMMENDATIONS
K No standard method exists for therapeutic drug moni-
toring of aminoglycosides by single daily dosing. Uniform
guidance, based upon carefully performed pharmaco-
kinetic/pharmacodynamic studies on the optimal timing
and method of therapeutic drug monitoring with single-
daily dosing regimens, would be of great assistance.319
K It is generally recommended that patients receiving
extended-dosing interval aminoglycosides should have
aminoglycosides administered at even greater dosing
intervals if mild or moderate degrees of underlying renal
impairment exist. Optimal therapeutic monitoring in
the setting of infrequent dosing intervals for patients
with underlying CKD needs to be standardized and
uniform recommendations need to be provided by
careful pharmacokinetic/pharmacodynamic observa-
tional studies.
K The impact of IHD and high-flux CRRTupon the efficacy
and toxicity of extended-duration dosing of aminoglyco-
sides needs further study. As membranes with greater
sieving coefficients come into greater use, the impact on
aminoglycoside elimination needs to be carefully con-
sidered. This could be investigated by RCTs using
standard dosing intervals vs. individualized dosing regi-
mens, with frequent drug-level monitoring and the use
of efficacy measures and kidney injury markers as
outcomes.
K The interaction between aminoglycosides and other anti-
microbial agents, and other therapeutic agents with
nephrotoxic potential needs to be more carefully
quantified. The degree of aminoglycoside-induced
nephrotoxicity alone vs. combination effects with such
drugs as vancomycin, amphotericin B, cephalosporins,
extended-spectrum penicillins, colistin, loop diuretics,
clindamycin, cisplatin, and nonsteroidal anti-inflamma-
tory agents needs to be more carefully examined in
observational studies.
AMPHOTERICIN B NEPHROTOXICITY
Amphotericin B has been the standard of treatment for life-
threatening systemic mycoses for over 50 years. This polyene
antifungal agent is insoluble in water and needs to be
solubilized with deoxycholate and given i.v. in the absence of
electrolyte solutions to maintain solubility. Despite its
broad-spectrum fungicidal activity against a large number
of invasive systemic mycoses, drug-induced nephrotoxicity is
common and remains the principal dose-limiting toxicity of
amphotericin B.328–330 Amphotericin B has numerous other
significant toxicities, including thrombophlebitis, electrolyte
disturbances, hypoplastic anemia, and systemic toxicity
associated with fever, chills, hypotension, and cytokine
release.331,332 AKI related to amphotericin B is clinically
significant and is associated with higher mortality rates,
increased LOS, and increased total costs of health care when
managing patients with systemic fungal infection.328,330
Over the past two decades, three major advances in
antifungal therapy have become clinically available: i) the
lipid formulations of amphotericin B; ii) the introduction of
the echinocandin class of antifungal agents; and iii) an
expanding number of azoles with extended activity against
a variety of fungal pathogens. Therapeutic alternatives to
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amphotericin B have been a welcome addition in the
management of systemic mycoses and selected, protozoan,
parasitic infections, but their incremental costs and tradeoffs
in spectrum of activity against fungal pathogens need to be
considered, in addition to their favorable toxicity profiles and
reduced potential for nephrotoxicity. A number of therapeu-
tic options are now available to the clinician when deciding
upon the choice for empiric or directed antifungal therapy.
Avoidance of risk of nephrotoxicity is one of the major, but
not the only, determinants when selecting antifungal therapy
at present.
3.8.6: We suggest using lipid formulations of ampho-
tericin B rather than conventional formulations of
amphotericin B. (2A)
RATIONALE
The broad-spectrum, polyene, antifungal agent amphotericin
B deoxycholate has been the mainstay of treatment for
systemic mycoses for decades. Despite its well-known toxicity
profile, the potent antifungal activity of amphotericin B, in
addition to its activity against certain protozoan parasites
(Plasmodium spp., Leishmania spp., Naegleria spp.), indicates
that this therapy will remain a standard agent in clinical
medicine for the foreseeable future.
Amphotericin B–induced nephrotoxicity is related to
multiple mechanisms, including ischemic injury and direct
tubular- and glomerular-cell membrane toxicity. Amphoter-
icin causes vasoconstriction of the afferent renal arteriole
along with a systemic inflammatory response that may
reduce renal blood flow. Amphotericin B also directly inserts
into human cellular membranes, where it disrupts membrane
permeability and physiology.331,332 Tubular epithelial cells
residing in the deep medullary regions of the kidney are
particularly susceptible to injury where considerable osmotic
stress exists across cell membranes even under physio-
logic conditions. The end result is enzymuria, loss of
renal tubular concentrating ability, renal tubular acidosis,
increasing urinary losses of potassium and magnesium, and
decreased glomerular function, resulting in azotemia and
decreased synthesis of erythropoietin. Amphotericin B–
induced nephrotoxicity is often accompanied by concomitant
administration of other potentially nephrotoxic agents
such as cyclosporine A, aminoglycosides, chemotherapeutic
agents, and a number of other potentially nephrotoxic
agents.328,329,333
Considerable efforts have been undertaken to try to limit
nephrotoxicity and permit the continued use of amphotericin
B deoxycholate for the management of systemic mycoses.
Simple maneuvers, such as salt repletion and provision of
adequate amounts of potassium, are beneficial in animal
models in the prevention of amphotericin B nephrotoxicity.
These measures have a mixed record in clinical practice, and
their capacity to prevent AKI when treating severe fungal
infections remain unclear. The relative ease and simple logic
of volume repletion and potassium supplementation during
amphotericin B therapy supports their routine use, despite
the relative lack of compelling clinical evidence to recom-
mend these maneuvers.
Various dosing strategies have also been instituted in an
attempt to limit amphotericin B–induced nephrotoxicity.
One strategy is to give amphotericin B as a continuous
infusion rather than a 2- to 4-hour infusion to limit
nephrotoxicity.329,334 While there is some suggestion that a
continuous infusion may limit nephrotoxicity, enthusiasm
for this strategy is tempered by the potential loss of some
antifungal activity. Amphotericin B exhibits concentration-
dependent antifungal activity, and continuous infusion of
low-doses of amphotericin B could result in suboptimal
protection for some patients with invasive fungal infec-
tions.334
Another common strategy is the administration of
alternate-day doses of amphotericin B, rather than daily
doses.335,336 This strategy is better tolerated and might reduce
nephrotoxicity without sacrificing efficacy in stable patients.
However, clear evidence that this strategy reduces nephro-
toxicity is not supported by large, adequately controlled
clinical trials as yet.
One of the major innovations in amphotericin B therapy
over the last 15 years has been the introduction of lipid
formulations of amphotericin to limit the problem of
nephrotoxicity associated with conventional amphotericin B
deoxycholate. Three lipid formulations are available includ-
ing: amphotericin B colloidal dispersion, amphotericin B
lipid complex, and liposomal amphotericin B. Amphotericin
B colloidal dispersion is formulated by amphotericin B
complexed with cholesteryl sulfate. Amphotericin B lipid
complex is composed of amphotericin B complexed with
dimyristoyl phosphatidylcholine and dimyristoyl phospha-
tidylglycerol. Liposomal amphotericin consists of amphoter-
icin B complexed with hydrogenated soy phosphatidyl-
choline, distearoylphosphatidylcholine, and cholesterol.337–340
Other formulations that might further reduce the risk of AKI
from amphotericin B include nanoparticle packaging in
micelles with polyaspartic acid.340
The safety and efficacy (in incidence of nephrotoxicity) of
lipid formulations of amphotericin have been studied in
numerous experimental and clinical trials with conventional
amphotericin B deoxycholate as the comparator.337–339,341–350
A detailed analysis of these various trials, and a number of
meta-analyses that have analyzed this clinical question,
concluded that the lipid formulations are less nephrotoxic
than amphotericin B deoxycholate.344,346 When feasible, we
recommend that lipid formulations supplant the use of
conventional amphotericin B deoxycholate to reduce the risk
of nephrotoxicity.
The incremental costs associated with the lipid formula-
tions and their relative efficacy for systemic mycoses remains
the subject of considerable debate. The existing evidence
would suggest that the overall risk-benefit ratio and cost-
effectiveness with these lipid formulations is essentially
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cost-neutral with amphotericin B deoxycholate.337,339
Attempts to increase the doses of lipid formulations of
amphotericin further to improve efficacy have resulted in
mixed results and are not recommended at present.342,343
Lipid formulations of amphotericin are less nephrotoxic but
require different dosing strategies (three- to five-fold higher
doses than deoxycholate formulations of amphotericin B).
Some of these agents continue to induce general systemic
toxicity reactions similar to those observed with the deoxy-
cholate formulation (e.g., amphotericin B colloidal dispersion).
3.8.7: In the treatment of systemic mycoses or parasitic
infections, we recommend using azole antifungal
agents and/or the echinocandins rather than
conventional amphotericin B, if equal therapeutic
efficacy can be assumed. (1A)
RATIONALE
Another approach to prevent amphotericin B nephrotoxicity
is to avoid polyene antifungal agents entirely and use alte-
rnative agents, such as the azoles and echinocandins.351–355
Azole antifungal agents inhibit sterol synthesis in fungal cell
membranes by blocking the activity of the 14-demethylase
enzyme essential for ergosterol synthesis. Nephrotoxicity
is an unusual event following the use of azole compounds.
The echinocandins are beta-glucan inhibitors that inter-
fere with cell-wall synthesis of fungal elements, and have an
entirely different mechanism of action from that of
amphotericin B. Both the azole compounds (voriconazole,
fluconazole, itraconazole, and posaconazole) and the echi-
nocandins (caspofungin, anidulafungin, and micafungin)
compare favorably to amphotericin B with respect to their
efficacy against a variety of the systemic mycoses. Both
classes of antifungal agents have the advantage of lacking
the intrinsic nephrotoxicity associated with amphotericin B
deoxycholate. Both the azole compounds and echinocandins
have proven to be less nephrotoxic than conventional
amphotericin B deoxycholate in observational studies,
historical control studies, and in small comparative trials.355
An important consideration in using these antifungal
agents is their relative efficacy with respect to the likely
pathogen that is targeted for treatment. Candida krusei is
intrinsically resistant to the azoles and Candida parapsilosis is
frequently resistant to the echinocandins. Amphotericin
B-resistant strains of selected Aspergillus spp. and Pseudal-
lescheria boydii are well described and require alternative
therapies.
There is currently insufficient evidence as to whether the
echinocandins, the azoles, or the lipid formulations of
amphotericin B differ significantly from each other with
respect to the risk of nephrotoxicity. No adequately
controlled, large, randomized studies have been reported to
date comparing the relative risk of nephrotoxicity amphoter-
icin B lipid formulations with either azole or echinocandin
antifungal agents. Such studies face the difficulty of recruiting
sufficient numbers of patients with similar baseline risk for
drug-induced AKI, and with a balance of exposure to other
potentially nephrotoxic agents. Until such time as these
studies are completed, no evidence-based recommendations
can be given about the relative risk of AKI attributable
directly to these antifungal agents.
RESEARCH RECOMMENDATIONS
K Some studies indicate that the liposomal form of
amphotericin B is less nephrotoxic than amphotericin B
lipid complex or amphotericin B colloidal dispersion.
RCTs in patients with systemic mycosis, with the rate of
AKI as a primary or secondary end-point, should be
conducted to answer this question.
K Innovative strategies to formulate amphotericin B in
microvesicles, nanoparticles, or micelles should be under-
taken to limit nephrotoxicity in treating fungal infections.
Clinical trials should compare existing formulations to
these novel formulations, and could generate cost-effective,
yet non-nephrotoxic derivatives of amphotericin B.
K Carefully selected combinations of antifungal therapies to
enhance efficacy and shorten duration of therapy may
limit toxicity and reduce costs in the treatment of fungal
infections. Investigations need to be carried out in the
laboratory and in clinical studies to improve the care of
patients with severe fungal infections. The costs and
complication rates of AKI, and other toxicities of short-
course combination treatment, should be compared to
standard dosing regimens of antifungal therapy.
K Markers of early nephrotoxicity and mechanisms to avoid
nephrotoxicity with amphotericin B formulations need
to be studied further in clinical investigations. These
antifungal agents are given for prolonged periods, and
should allow ample opportunity to test the validity of
novel biomarkers of drug-induced nephrotoxicity. A
group monitored with novel AKI biomarkers should be
compared to conventional monitoring of AKI, to
determine if one or more early biomarkers of kidney
injury add to standard clinical care in the prevention of
drug-induced AKI.
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Chapter 3.9: Other methods of prevention of AKI
in the critically ill
ON-PUMP VS. OFF-PUMP CORONARY ARTERY BYPASS
SURGERY
The type of cardiac surgery is important in the discussion on
risk for kidney problems associated with this surgery.
Valvular procedures or aorta surgery are associated with a
higher risk. One of the most controversial risk factors is
on-pump vs. off-pump coronary artery bypass surgery.
Off-pump coronary artery bypass obviously removes the
bypass circuit but can be associated with greater hemo-
dynamic instability secondary to ventricular compression as
the heart is manipulated to access the coronary arteries.356
It is possible, with standard operative techniques, to perform
coronary artery bypass surgery (but not valve surgery)
without using cardiopulmonary bypass. This technique is
known as ‘‘off-pump’’ coronary artery bypass surgery.
It has been hypothesized that preservation of physiologic
renal perfusion by avoidance of cardiopulmonary bypass
would partially nullify the risk of AKI in patients receiving
coronary artery bypass surgery. Potential benefits that have
been posited for off-pump coronary artery bypass (compared
to on-pump procedures) are reduced mortality, reduction of
AKI risk (and in particular, acute dialysis, which is associated
with a perioperative mortality of 42% in the Society of
Thoracic Surgeons database), reduced risk of cerebral
dysfunction (due to stroke and neurocognitive dysfunction,
the latter sometimes referred to as ‘‘pump head’’), reduction
in ICU stay and days in hospital, and reduction in atrial
fibrillation. As in other areas covered by these guidelines only
mortality, risk for RRT, and AKI risk are addressed as end-
point measures. It must, however, be remembered that the
potential benefits of off-pump coronary artery bypass might
be predominantly outside these areas of focus.
3.9.1: We suggest that off-pump coronary artery bypass
graft surgery not be selected solely for the purpose
of reducing perioperative AKI or need for RRT. (2C)
RATIONALE
As detailed in Suppl Tables 15 and 16, which summarize
RCTs, the balance of the potential benefit and harms is
uncertain and the quality of the evidence is weak, that off-
pump surgery is associated with better outcomes of the three
end-points used in these guidelines: incidence of AKI, need
for RRT, or mortality.
A recent good-quality RCT357 was performed in 2203
patients (only B8% of patients with SCr 41.5mg/dl
[4133 mmol/l]) (Suppl Table 16). There was no significant
difference between off-pump and on-pump coronary artery
bypass graft in the rate of the 30-day composite outcome.
The rate of the 1-year composite outcome was higher for
off-pump than for on-pump coronary artery bypass graft.
Follow-up angiograms in the majority of the patients
revealed that the overall rate of graft patency was lower in
the off-pump group than in the on-pump group (82.6% vs.
87.8%, Po0.01).
A comprehensive meta-analysis including RCTs, and
abstracts from the proceedings of scientific meetings through
February 2010, was recently published.358 AKI was defined
by a mixture of criteria, including biochemical parameter,
urine output, and dialysis requirement. Mortality was
evaluated among the studies that reported kidney-related
outcomes. This analysis compared off-pump with the more
traditional on-pump technique. Off-pump coronary artery
bypass graft was associated with a statistically significant
40% lower odds of postoperative AKI and a nonsignificant
33% lower odds for dialysis requirement. Within the
selected trials, off-pump coronary artery bypass graft surgery
was not associated with a significant decrease in mortality.
It is apparent from this meta-analysis that the trials
were clinically heterogeneous, particularly in regards to
their definitions of kidney outcomes, and mostly were of
poor to fair quality (based on the Jadad score). The very
low event rates (often 0–1 patients) make the estimates
suspect and highly imprecise. There is also a question of
publication bias. There are several large trials in progress
that are likely to generate more definitive data. In chronic
dialysis patients, there are observational US Renal Data
Systems data to weakly support the use of off-pump
technique (slightly lower mortality). However, with any
technical advance that is introduced in certain centers,
institutional familiarity with the technique, operator experi-
ence, and characteristics of the population referred to
the center are likely to be important modulators of out-
comes. In conclusion, based on the analysis of the RCTs
and the recent meta-analysis, the Work Group found
that there was not enough evidence to recommend off-
pump coronary artery bypass for reducing AKI or the need
for RRT.
RESEARCH RECOMMENDATION
K Further studies are needed to clarify the role of off-pump
coronary artery bypass in patients with increased risk
for AKI.
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N-ACETYLCYSTEINE (NAC)
3.9.2: We suggest not using NAC to prevent AKI in
critically ill patients with hypotension. (2D)
RATIONALE
NAC has been most frequently applied in the prevention
of CI-AKI, and this topic is discussed in more detail in
Chapter 4.4.
NAC is a modified form of L-cysteine, an amino acid that
is a precursor to reduced glutathione that can regenerate
glutathione stores. It is known to be a potent antioxidant that
scavenges oxygen-free radicals in the body. It also has
vasodilatory properties derived from enhanced nitric oxide
availability.359 NAC has been shown to attenuate ischemic
and nephrotoxic ARF in a number of animal studies,360–363
and the pharmacological characteristics of NAC that could
play a role in the prevention of AKI have recently been
summarized.364 NAC undergoes extensive first-pass metabo-
lization in the gastric mucosa and liver. This results in a very
low oral bioavailability, with substantial intrapatient varia-
bility (3–20%), as well as inconsistency between available
oral products. The plasma half-life of acetylcysteine after
i.v. injection is approximately 6–40minutes, and there is
extensive binding to plasma and tissue proteins through
the sulfhydryl group. Virtually no acetylcysteine can be
detected in the systemic circulation after i.v. or oral
administration, suggesting that any potential therapeutic
benefit must be due to secondary effects such as the
induction of glutathione synthesis, rather than due to direct
effects. As these secondary effects are not directly measurable,
the determination of the optimal dosage schedule has been
necessarily empirical.365
A particularly important problem with NAC is whether it
can alter SCr independent of a change in GFR. NAC has been
reported to decrease SCr levels in subjects with normal
kidney function. This reduction in SCr was not accompanied
by a change in serum cystatin C levels. This suggests an effect
independent of a change in GFR, such as an increase in
tubular secretion of creatinine or a decrease in creatinine
production.366 By contrast, in vitro analysis on the effect of
NAC on SCr367 showed no analytical interference with the
measurement of SCr by any of the commonly used analytical
methods. Haase et al.,368 studied 30 patients with normal
kidney function who received i.v. NAC for 24 hours in
association with cardiac surgery. No change in the ratio of
SCr to cystatin C, compared to baseline values, was observed
at the end of the 24-hour infusion or 48 hours after the
cessation of the infusion. In addition, there was no effect on
urinary creatinine excretion during the infusion. However, in
clinical practice, NAC is generally recommended for patients
with CKD, with an eGFR o60ml/min per 1.73 m2. Mainra
et al.,369 observed no change in SCr or cystatin C at 4, 24, or
48 hours after administration of a single 600-mg dose of NAC
to 30 patients with CKD Stage 3. Finally, Rehman et al.,370
tested the potentially confounding effect of NAC in a CKD
population (Stages 3–5) following doses of NAC currently
recommended for prophylaxis of AKI. There was no effect of
NAC on either SCr or cystatin C levels.
It is thus safe to conclude that NAC, in doses currently
recommended for prophylaxis of AKI, has—by itself—no
effect on SCr or cystatin C levels. In addition, NAC is
inexpensive and appears to be safe, although it may have
some detrimental effects on myocardial and coagulation
function.371–373 The ‘‘safety’’ of NAC should further be
amended, particularly when high i.v. doses are used, as in
some of the RCTs in CI-AKI. When prospectively studied in
acetaminophen poisoning, i.v. NAC produced anaphylactoid
reactions in up to 48% of participants.374 Although most of
these reactions were mild, at least one death has been
reported in a patient with asthma.375 It should also be noted
that the doses of acetaminophen used are still much higher
than in the ‘‘high doses’’ used, particularly in AKI trials.
Besides the prevention of CI-AKI, NAC has also been tested
in the setting of cardiothoracic surgery and liver transplanta-
tion, and in hypotensive critically ill patients.
NAC IN CRITICALLY ILL PATIENTS
3.9.3: We recommend not using oral or i.v. NAC for
prevention of postsurgical AKI. (1A)
RATIONALE
The above recommendation is based on an evaluation of
the available literature on prevention studies with NAC in
cardiovascular and abdominal vascular surgery, and liver
transplantation.
The tables summarize the RCTs where either oral or i.v.
NAC was compared to placebo; only studies containing a
minimum of 50 patients in each study arm have been
included. In addition, a recent meta-analysis is available,376
containing 10 studies involving a total of 1193 adult patients
undergoing major surgery. Seven studies (1003 patients)
evaluated the effects of NAC in patients undergoing cardiac
surgery, and three of these (508 patients) exclusively studied
patients with pre-existing renal impairment. Two studies
(111 patients) evaluated the effects of NAC on patients
undergoing abdominal aneurysm repair surgery and one
study (79 patients) was of patients undergoing major
abdominal cancer surgery. End-points in most of the studies
were mortality, need for RRT, or varying increases in
postoperative SCr concentrations compared to preoperative
SCr values.
Suppl Tables 17 and 18 summarize the five studies where
NAC was compared to placebo in patients undergoing
cardiac surgery and who were not exposed to radiocontrast
media.377–381 All five studies analyzed the effects of NAC in
patients with moderate, pre-existing renal functional impair-
ment. Surgery included elective or emergency coronary artery
bypass graft operations or heart valve surgery. NAC was given
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i.v. in most of the studies; mortality was evaluated at different
follow-up times; either in-hospital or at 30 or 90 days. Only
one study found a significantly lower mortality at 30 days.377
None of the studies found either a difference in need for RRT,
or in AKI defined as variable changes in SCr after surgery. All
studies were of A-level quality. Two relatively small studies
evaluated the effects of NAC on patients undergoing
abdominal aneurysm repair surgery382,383 and did not find
any protective effect on renal function.
Further, one meta-analysis376 did not find evidence that
NAC used perioperatively can alter mortality or renal
outcomes after major cardiovascular or abdominal cancer
surgery when radiocontrast agents are not used. In none of
the studies were significant treatment-related adverse effects
of NAC reported. These reports suggest that NAC, in the
context of cardiovascular surgery, is not associated with
increased risk of mortality, surgical re-exploration, or
allogeneic transfusion.
Only one single study has compared NAC to placebo in
critically ill patients (Suppl Table 18).384 One hundred and
forty-two ICU patients with new-onset (within 12 hours) of
at least X30 consecutive minutes of hypotension and/or
vasopressor requirement were randomized to receive either
oral NAC or placebo for 7 days, in addition to standard
supportive therapy. AKI was defined as X0.5mg/dl
(X44 mmol/l) increase in SCr. Patients who received NAC
had an incidence of AKI of 15.5%, compared to 16.9% in
those receiving placebo (NS). There were no significant
differences between treatment arms in any of the secondary
outcomes examined, including incidence of a 50% increase in
SCr, maximal rise in creatinine, recovery of renal function,
length of ICU and hospital stay, and requirement for RRT.
Mortality in both arms was 10%. Based on this single study,
which is underpowered but did not show any beneficial effect
on incidence of AKI, need for RRT, or patient mortality, we
suggest not using NAC to prevent AKI in critically ill patients
with hypotension.
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